The effects of smokeless tobacco administration on perception of effort and cognitive task in men by T. Zandonai
UNIVERSITA’ DEGLI STUDI DI VERONA 
 
 
DEPARTMENT OF 
PATHOLOGY AND DIAGNOSTICS 
 
GRADUATE SCHOOL OF 
TRANSLATIONAL BIOMEDICAL SCIENCES 
 
DOCTORAL PROGRAM IN 
TRANSLATIONAL BIOMEDICINE 
CYCLE XXVI 
(2011-2013) 
 
 
PhD THESIS 
 
THE EFFECTS OF 
SMOKELESS TOBACCO ADMINISTRATION 
ON PERCEPTION OF EFFORT AND COGNITIVE TASK IN MEN 
 
S.S.D BIO14/FARMACOLOGIA 
 
 
 
 
Coordinator: Chiar. mo Prof. Cristiano Chiamulera 
Tutor:   Chiar. mo Prof. Cristiano Chiamulera  
 
 
Doctoral Student:  
Dott. Thomas Zandonai 
!! ii!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedicated to Giovanni Zandonai 
named “Gianetto”, a free man !!!!!!!!!!!!!!!!!!!!!!!!!
 
!! iii!
CONTENTS 
 
Abstract…………………………………………………………………………............………….1 
List of studies……………………………………………………………………………..............4 
List of abbreviations……………………………………………………………………..............5  
 
1. GENERAL INTRODUCTION……………...........................................................................7 
1.2 Snus…………………………………………………………………………….............7 
1.2 Aim of the thesis……………………………………………………………..............11 
 
2. STUDY I 
Smokeless tobacco (snus) use among winter sport athletes in Italy………….............12 
2.1 Introduction……………………………………………………………………...........12 
2.2 Materials and methods……………………………………………..........................13 
2.2.1 Participants……………………………………………….........................13  
2.2.2 Instruments……………………………………………….........................13 
 2.3 Results……………………………………………………………….........................15 
 2.4 Discussion……………………………………………………...……........................22  
 
3. STUDY II 
Effects of snus administration on exercise endurance in men…………………............25 
3.1 Introduction……………………………………………………………………...........25 
3.2 Materials and methods.......................................................................................26 
3.2.1 Participants..........................................................................................26 
3.2.2 General Design…………………………………………………...............26 
3.2.3 Protocol...............................................................................................27 
3.2.4 Materials……………………………………………………………...........30 
 3.3 Results………………………………………………………………………..............34 
 3.4 Discussion……………………………………………………………………............42 
 
4. STUDY III 
Effects of snus administration in Iowa Gambling Task in men…………………............45 
4.1 Introduction……………………………………………………………………...........45 
4.2 Materials and methods.......................................................................................46 
4.2.1 Participants..........................................................................................46 
4.2.2 General Design....................................................................................46 
4.2.3 Protocol...............................................................................................47 
4.2.4 Materials..............................................................................................48 
 4.3 Results…………………………………………………………………...…...............51 
 4.4 Discussion..........................................................................................................54 
 
5. STUDY IV 
Acute effect of snus on physical performance and perceived cognitive load on 
amateur footballers............................................................................................................56 
5.1 Introduction……………………………………………………………………...........56 
5.2 Materials and methods.......................................................................................57 
5.2.1 Participants..........................................................................................57 
5.2.2 General Design …………………………………………….....................58 
5.2.3 Protocol…………………………………………………………................59 
5.2.4 Materials…………………………………………………………...............61 
 5.3 Results…………………………………………………………………………...........65 
 5.4 Discussion……………………………………………………………………….........68 
 
6. CONCLUSIONS………………………………………………………………….....................73 
 
7. REFERENCES………………………………………………………………….......................74 
 
ACKNOWLEDGMENTS......................................................................................................84  

!! 1!
Abstract 
Some evidence suggests that smokeless tobacco (snus) is widespread among 
athletes from countries where a general population use it. A proliferation of nicotine 
use in the sport environment has been observed in recent years. Thus, nicotine has 
been placed on World Anti-doping Agency’s (WADA) 2013 Monitoring Program. 
In literature it is little known regarding the actual effects of this product, especially 
on endurance performance, on a cognitive performance and on football players’ 
performance. Therefore, the main objective of the present thesis was to study the 
effects of snus administration during these three performances. To achieve this 
goal we designed four studies. 
First of all, we performed two surveys (STUDY I) to investigate snus past 
experience and current use (Survey I) and reinforcement effects of snus (Survey II) 
in a sample of winter sport athletes in Northern of Italy. Data collection was 
performed by administering a questionnaire to winter sport athletes after 
competitive ski races or during training in Italian Dolomites (Northern Italy). 
Smoking status and dual snus-smoking use information were also collected. Eighty 
out of a one hundred-eight participants (74%; 80.5% of males and 61.1% of 
females) tried snus at least once. Fifty-four participants were current snus users 
(50% out of the total). Forty-one participants were current smokers (38%). Smoking 
status and reinforcement effects of snus use (Survey II) information were also 
collected with the modified Cigarette Evaluation Questionnaire (mCEQ). 
Comparison between occasional vs. regular snus users (61 subjects) showed a 
statistically significant difference for satisfying (p<0.0088), calm (p<0.0252) and 
enjoying (p< 0.0001) mCEQ items. Survey I data confirmed snus use among 
athletes, and showed a higher smoking prevalence in this sample than in the 
general population. Survey II confirmed that snus use is reinforcing in current snus 
users. The findings were collected among athletes coming from a country where 
there is not socio-cultural snus tradition and where marketing is banned. In this 
STUDY I we hypothesize that both a successful ‘sport’ role–model, and the 
availability of accepted and flexible nicotine ‘multi-delivery’ may be the determinant 
factors of this phenomenon.  
The aim of the second study (STUDY II) was to firstly investigate the effects of snus 
on the perception of fatigue during an endurance exercise in men. The study was a 
double-blind placebo controlled crossover design study. We recruited 14 male non-
!! 2!
smokers and non-snus users. Subjects were studied during three sessions on 
cycle-ergometer: experiment 1 (EXP1) consisted on an incremental exercise test to 
determine Wmax (maximal aerobic power output); EXP2 and EXP3 consisted on 
snus or placebo administration followed by an exercise at 65% Wmax until 
exhaustion. During the EXP2 and EXP3 the global rating of perceived exertion 
(RPE) was recorded, using the 15-point Borg scale. Before and after all 
experiments, subjects were administered the Profile of Mood of State questionnaire 
(POMS) and tested by means of Transcranial Magnetic Stimulation (TMS) to 
assess changes in cortico-motor excitability due to the prolonged exercise. In this 
STUDY II we observed that snus does not change RPE compared to placebo 
condition; this means that the sought effect could not be an improvement of fatigue 
during an endurance exercise until exhaustion.  
In the third study (STUDY III) our aim was to measure the effect of snus 
administration on the Iowa Gambling Task (IGT) an experimental test to study 
decision-making process. We recruited 40 male non-smokers and non-snus users. 
Subjects were randomized to blindly receive snus or placebo on two different days 
according to a cross-over design. No significant differences were observed during 
the IGT performance under both conditions (snus vs. placebo).  
In the last study (STUDY IV) we assessed the effect of Snus on physical 
performance, heart rate variability, subjective arousal, and mental workload in non-
smokers non-snus user amateur football players. Participants were administered 
either snus or placebo forty minutes prior to a fitness test battery. Hearth rate 
values, global ratings of perceived exertion, perceived arousal and, perceived 
mental workload were collected after the snus or placebo administration. The 
fitness test battery consisted of 4 tests: Handgrip Test, Counter-movement Jump, 
Agility test and Yo-yo intermittent recovery test. Significant differences were 
observed in agility test performance (18.82 ± 0.81 vs. 18.47 ± 0.62 seconds), level 
of mental fatigue before the experimental session (4.17 ± 2.38 vs. 2.94 ± 1.89 
points), and perceived mental load after the overall experimental session (6.37 ± 
2.16 vs. 5.44 ± 1.83 points) (snus vs. placebo conditions, respectively). The 
outcome of the STUDY IV suggested that snus, due to its detrimental effects on 
performance, is counter-indicated as an ergogenic aid.  
This research project aimed to assessed the effects of snus administration in non-
smokers non-snus users healthy male subjects on endurance performance, 
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cognitive performance and football players’ performance showed that snus 
administration (vs. placebo condition) did not improve exercise and cognitive 
performance. 
   
  
!! 4!
List of studies 
The present thesis is based on the following studies, which are referred to in the 
text by their Roman numerals: 
 
STUDY I Smokeless tobacco (snus) use among winter sport athletes in Italy 
 
 
STUDY II Effects of snus administration on exercise endurance in males * 
 
 
STUDY III Effects of snus administration in Iowa Gambling Task in males ** 
 
 
STUDY IV Acute effect of snus on physical performance and perceived cognitive 
load on amateur male footballers *** 
 
 
 
 
 
 
 
 
* In collaboration with: 
Laboratory Action Perception (LAP), School of Exercise and Sport Sciences, 
University of Verona, Italy 
Exercise Physiology Laboratory, School of Exercise and Sport Sciences, University 
of Verona, Italy 
Department of Pathology and Clinical and Experimental Medicine, University of 
Udine, Italy 
 
** In collaboration with: 
Laboratory of Experimental Psychology, School of Psychology, University of 
Sussex, Brighton, UK 
 
***In collaboration with: 
Faculty of Sport Sciences, University of Granada, Spain  
!! 5!
List of abbreviations  
AC   Abstinence Condition  
AT   Agility test 
BMI   Body Max Index  
CI   Confident Interval  
CMJ   Countermovement jump 
CO   Carbon Monoxide 
CO2   Carbon dioxide 
CQ   Control Questions 
DM   Decision-Making 
ESI   Positive Electrospray Ionisation  
EU   European Union 
EXP1   Experiment one 
EXP2   Experiment two 
EXP3   Experiment three 
F.I.S.I.  Italian Winter Sports Federation 
FTB   Fitness Test Battery 
HDT   Hand dynamometric test 
HHb   Deoxy-haemoglobin  
HPLC   High Performance Liquid Chromatography 
HR   Heart Rate  
HRV   Heart Rate Variability 
IGT   Iowa Gambling Task 
Mb    Myoglobin 
mCEQ  Cigarette Evaluation Questionnaire  
MD   Medical Visit 
N   Number of participants 
NIRS   Near-infrared Spectroscopy  
O2Hb   Oxy-haemoglobin   
OST   Oral Smokeless Tobacco 
POMS  Profile of Mood of State questionnaire  
PR   Perceived Readiness 
Q’   Cardiac output  
RER   Respiratory Exchange Ratio   
!! 6!
rMSSD Root-mean-square difference of successive normal R-R 
intervals 
RPE   Rating of Perceived Exertion  
RPM   Revolutions per minute 
Rri   R-R interval 
SC   Satiety Condition  
SD   Standard Deviation 
SE   Standard Error 
SEI   Side Effects interview 
SIM   Selected Ion Monitoring  
SO   Substance (Snus/Placebo) Out   
SP   Swedish Snus Placebo 
SS   Swedish Snus  
STPs   Smokeless Tobacco Products 
SV   Stroke Volume  
T0   Time zero 
T1   Time one 
THb   Total haemoglobin  
Tmax   Maximum Time 
TMS   Transcranial Magnetic Stimulation  
V ̇CO2   Rate of CO2 production  
V ̇E O2   Expiratory minute ventilation  
V ̇O2   Consumption Rate  
VAS    Visual Analogue Scale 
VL   Vastus lateralis muscle  
VO2max   Maximal Oxygen Uptake  
W   Watt 
WADA  World Anti-Doping Agency 
Wmax   Maximal aerobic power output  
YYT   Yo-yo recovery intermittent test 
[G]b   Blood glucose concentration  
[Hb]b   Blood haemoglobin concentration 
[La]b   Blood lactate concentration   
 
!! 7!
1. GENERAL INTRODUCTION 
Smokeless tobacco (ST) is taken orally or nasally without burning the product at the 
time of use. Oral smokeless tobacco (OST) products are placed in the mouth, 
cheek or lip and sucked (‘dipped’) or chewed. Nicotine is considered to be a major 
addictive component in smokeless tobacco products (STPs) and the total nicotine 
content in different STPs varies, depending on various factors, including the kind of 
tobacco used (Ramström 2000). Nicotine is a psychomotor stimulant and this raises 
the issue of whether such use constitutes that of a performance-enhancing drug 
(Chiamulera et al., 2007). One way of consuming nicotine is through the use of 
snus. 
 
1.1 Snus  
Smokeless Tobacco Commission (ESTOC) has defined snus as, “an oral 
smokeless tobacco product traditionally used in Sweden that is manufactured using 
a tobacco heat- treatment process” (Rutqvist et al., 2011). Snus is an air-cured, 
finely ground, heat pasteurized tobacco product and it is marketed in portion-bag 
packets (pouches) (Figure 1), in a variety of flavors (Andersson et al., 1995; Lunell 
and Lunell 2005). This OST has always been the predominant form of ST in 
Sweden, which is the only country in Europe that can sell legally snus (Anon 1992).  
 
 
Figure 1. Portion-bag packets of snus.  
 
The snus is typically held in the mouth between the upper lip and the gum for 
approximately 30-45 minutes before it is thrown out (Foulds et al., 2003). The dose 
of nicotine cannot be predicted simply from the nicotine content of cigarettes, 
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tobacco, or smokeless tobacco products (Benowitz and Jacob 1984). Nicotine is 
absorbed rapidly when tobacco smoke reaches the small airways and alveoli of the 
lung. It takes 10-19 seconds for nicotine to pass through the blood-brain barrier 
(Benowitz 1999). In contrast, the use of smokeless tobacco products results in a 
gradual rise of nicotine blood concentrations, with little arterial-venous 
disequilibrium (Le Houezec and Benowitz 1991). Nicotine blood levels through 
smokeless tobacco paths of nicotine intake tend to reach a peak after about 30 
minutes, with the levels continuing and decreasing slowly over 2 or more hours 
(Benowitz 1999; Hukkanen et al., 2005). Foulds et al (2003) showed that nicotine 
plasma levels from smoking the cigarette rose more rapidly than for the oral 
products (Figure 2). According to Lunell and Curvall (2011) the mean time to 
maximum nicotine plasma concentration (Tmax) is 37.1 ±10.2 min (range: 24–60 
min) for 1 g portion (8.7 mg nicotine) of snus.  
 
 
 
Figure 2. Nicotine plasma concentration in cigarette and STPs. Venous blood 
concentrations in nanograms of nicotine per milliliter (ng/ml) of plasma as a function of time 
for various nicotine delivery systems. Image taken from Foulds et al 2003.  
 
Andersson et al (1994) showed that 10-20 % of the nicotine originally present in the 
snus is absorbed via the buccal mucosa and reaches the systemic circulation 
(Andersson et al., 1994; Andersson et al., 1995). Therefore, only 1-2 mg of nicotine 
is absorbed into the blood from a one-gram pinch containing approx. 10 mg of 
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nicotine. The amount of nicotine absorbed varies greatly among individuals. Lunell 
and Lunell (2005) observed that the variation in extraction rates among different 
snus users was 50 to 300% greater than the variation from portion to portion in the 
same snus user. The percentage of nicotine extracted from snus is 22%-44% 
(Digard et al., 2013; Lunell and Lunell 2005). The prolonged elimination of nicotine 
in snus users has been attributed to continued absorption of nicotine released from 
the mucous membrane or to absorption of nicotine that has been swallowed (Figure 
3) (Benowitz et al., 1989; Lunell and Lunell 2005).  
 
 
Figure 3. Nicotine plasma concentration–time curves of STPs. Mean nicotine plasma 
concentration–time curves obtained following hourly use of four different brands of Swedish 
snus and 2-mg Nicorette chewing gum. Image taken from Lunell and Lunell 2005.  
 
The use of snus among young people has been increasing in countries such as 
Norway (SSB 2013), Sweden (Norbert 2013) and in the USA (Bhattacharyya N 
2012). In literature are presents some studies about differences in gender for snus 
use (Digard et al., 2009; Huhtala et al., 2006, Wiium et al., 2009), with a lower 
number of female snus users, and most of them self-reporting less attractiveness of 
snus compared to other forms of tobacco use. It is interesting to note that in these 
surveys the prevalence of snus use among females was greater than that reported 
in the general female population of other countries (e.g., Sweden see Digard et al., 
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2009)  even if the small sample size cautions about a comparison.  
Some studies showed a high use of a psychoactive substance (nicotine) through 
snus, among athletes in a winter sporting environment (Zandonai et al., 2013; 
Marclay and Saugy 2010: Marclay et al., 2011). Three studies showed high levels 
of snus use among Scandinavian athletes (Mattila et al., 2012; Alaranta et al., 2006; 
Martinsen et al., 2012), and in U.S sport environment (Green et al., 2001; Severson 
et al., 2005). Chiamulera et al (2007) argued whether “subjects who are taking ST 
benefiting from legal doping?“. He suggested that ST effects should be tested on 
field parameters, which are relevant to the specific desired effect in sports rather 
than the ‘traditional’ psychometric measures. But only from 2012, nicotine has been 
placed on WADA's 2012 Monitoring Program in order to detect potential patterns of 
abuse. 
In literature it is observed a snus use in sports environment. In contrast to this there 
is not literature that show the effect of snus on sport and cognitive performance. 
There are many articles about nicotine effects administered with OST as nicotine 
gum (Hindmarch et al., 1990; Sherwood et al., 1992; Parrot and Winder 1989; 
Philips and Fox 1998). Other hand, findings on the effects of nicotine in healthy 
abstinent smokers and non-smokers have been inconsistent. While some studies 
have shown a reduction in reaction time and an increase in accuracy scores 
following smoking or administration of 2 mg of nicotine via other routes in acutely 
abstinent smokers, satiated smokers and non-smokers (Kerr et al., 1991; Sherwood 
et al., 1992; Houlihan et al., 2001), others have shown no effect of subcutaneous 
injections of 2 or 4 mg nicotine gum on this task in similar groups (Hindmarch et al., 
1990; Foulds et al., 1996). Another group has reported impaired accuracy in 
abstinent smokers immediately following smoking (Spilich et al., 1992). In a another 
study using this task by Grobe et al (1998), half of the memory sets were presented 
concurrently with a distracting tone. Nicotine nasal spray, in comparison to placebo, 
significantly reduced scanning rates in the presence of distracting stimuli, in acutely 
abstinent smokers but not in non-smokers. In addition, while Foulds et al (1996) 
found no effect of subcutaneous nicotine on digit recall in abstinent smokers, non- 
smokers recalled more digits after experimental administration of nicotine than 
saline. Finally, neither Powell et al (2002) nor Jones et al (1992) found an effect of 
smoking or subcutaneous nicotine injection on reverse or forward digit span in 
either acutely abstinent smokers or non-smokers. 
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1.2 Aim of the thesis 
Most of sport practice has developed empirically and sports insiders have not yet 
realized the importance to appraise the evidence base, especially when using 
substances. We have also to emphasize that in literature there are few studies that 
have shown substances effectiveness (e.g. cognitive enhancer administration). In 
fact, there are anecdotal, but sparsely experimental, evidence for efficacy in healthy 
subjects: people taking cognitive enhancer drugs subjectively report a perceived 
improvement of performance. In spite of lack of objective evidence, the use is 
increasingly widespread (Maher 2008; Chiamulera 2011).  
Considering these considerations and the gaps in literature, the current body of 
work was designed to investigate four aspects of snus administration in healthy 
male participants. Therefore, four main issues were addressed: 
1. How many athletes use snus in a country with no socio-cultural tradition and 
marketing of snus? 
2. Does snus administration increase endurance performance and perception 
on effort?  
3. Does snus administration change Decision-Making process? 
4. Does snus use affect physical performance, heart rate variability, and 
perceptual responses in amateur footballers? 
To answer these questions, we performed four studies. 
In the first study (STUDY I) we explored snus use by investigating self-report past 
snus experience and current use in a sample of winter sport athletes in Northern 
Italy. In the same study we aimed to know the pattern of snus-induced reinforcing 
effects subjectively described by skiers. 
In the STUDY II we investigated the snus effects on exercise endurance correlated 
with the perception of fatigue along with a range of physiological and neuro-
physiological parameters. 
The STUDY III investigated the effect of snus administration in IGT as a validated 
tool to study Decision-Making process.  
Finally, in the STUDY IV we assessed the effect of snus on physical performance, 
heart rate variability, and subjective arousal and mental workload in non-smokers 
non-suns users amateur football players. 
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2. STUDY I 
Smokeless tobacco (snus) use among winter sport athletes in Italy 
 
2.1 Introduction 
Smokeless tobacco is a form of tobacco use that is widespread in North America 
and Scandinavian countries such as Sweden, Norway and Finland. In particular, in 
the latter countries, the moist snuff form called ‘snus’ is the most widely used and 
popular among young people (Huhtala et al., 2006; Stenbeck et al., 2009).  
The prevalence and the socio-demographic patterns of snus use have been 
extensively investigated and described (Digard et al., 2009; Furberg et al., 2006; 
Lundvqvist et al., 2009; Overland et al., 2010). In Italy, although snus is not 
marketed in accordance to the European Union ban, (Anon, 1992; Ahlbom et al., 
2007) it could be however purchased via Internet. Recently, there were some 
anecdotal reports about the use of snus in alpine skiers participating at ski 
championship races across the alpine area, Europe. A preliminary survey, which we 
conducted during competitive events in the Italian Dolomites, showed that 
approximately half of the interviewed skiers were current snus users. The use of 
snus in this particular segment of young population is somehow surprising 
considering that it takes place in a country where there is not socio-cultural tradition 
and marketing of snus.  
Moreover, there are currently unanswered psychobiological questions such as the 
sought and the subjective reinforcing effects experienced by this specific athletic 
population. In fact, from a psychobiological standpoint, snus is a delivery of a 
psychoactive and addictive substance, nicotine (Fagerstrom and Schildt, 2003; 
Henningfield et al., 1997). Snus users have positive expectancies about effects 
(Wiium and Aaro 2011), report subjective pleasure (Caldwell et al., 2010), exhibit 
dependent behavior and withdrawal symptoms (Hatsukami et al., 1987; Timberlake 
2008). Considering the existence of dual snus-smoking users, a ‘multi-delivery’, 
flexible, pattern of nicotine self-administration is the psychobiological mechanism 
that could explain snus use behavior (Post et al., 2010). 
The general aim of our investigation is to further extend our preliminary 
observations about the snus use phenomenon, and to investigate the potential 
psychobiological reasons: why this segment of Italian winter sport athletes is taking 
snus? Therefore, the primary scope of Survey I was to explore this phenomenon by 
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investigating self-report past snus experience and current use in a sample of winter 
sport athletes. The Survey II aimed to know the pattern of snus-induced reinforcing 
effects subjectively described by skiers. Considering the lack of background 
knowledge about snus use in Italy, these were pilot surveys, which were designed 
without any ad-hoc assumption about social models, gateway hypothesis or other 
inductive questions. 
 
2.2 Materials and methods 
2.2.1 Participants 
In Survey I we interviewed 108 athletes who practice winter sports. One-hundred-
five participants were agonistic athletes (97.2%), i.e. being in possession of the 
medical certificate of fitness in order to participate in agonistic races organized by 
Italian Federation of Winter Sports (F.I.S.I.). The three winter sports were alpine 
skiing, nordic skiing and biathlon (i.e., rifle shooting and nordic skiing).  
 
2.2.2 Instruments 
The Survey I questionnaire was divided into three main sections. First section 
investigated demographic data, the winter sport(s) practiced, age of start, agonistic 
level, and other practiced sports. Section two collected self-report data about snus 
use. Past snus experience was asked with the questions: “Have you ever tried 
snus? How many times in your lifetime?’’ The answers were 1 ‘‘I have never tried’’, 
2 ‘‘I have tried once’’, 3 ‘‘I have used snus 2–50 times’’, or 4 ‘‘I have used snus 
more than 50 times’’. Answers 2 or 3 were defined as ‘limited snus experience’, 
whereas answering to “…more than 50 times” (Answer 4) was defined as ‘extensive 
snus experience’. The age of the first snus experience was also recorded. The 
current snus use was asked by the question ‘‘Do you use snus at present?’’ with 
answers ‘‘not at all’’, ‘‘occasionally’’ (less than once a day, defined as ‘occasional 
use’), or, ‘‘once a day or more often’’ (defined as ‘regular use’) (Huhtala et al., 
2006). Section three investigated current smoking status. At the question “Do you 
smoke at the present?”, answers were “no”, “occasionally” (less than one cigarette 
a day, defined as ‘occasional smoking) and “yes” (one or more cigarette a day, 
defined as ‘regular smoking’). The number of cigarettes smoked per day was also 
recorded. 
We collected data after two competitive races of alpine skiing (80% of the 
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participants) or during training (20% of the participants) in Italian Dolomites 
(Northern Italy). Each questionnaire was made anonymous by an alphanumeric 
code (2-letter name initials and 8-digit date of birth). Gender differences in 
prevalence were analyzed by contingency table analysis with Fisher’s exact test 
(GraphPad Prism 4). Analysis was reported as odds ratios and confidence intervals 
(C.I.). 
In Survey II sixty-one participants who reported past or current snus use were 
included. Questionnaire was divided into three main sections. First section 
investigated demographic data, the winter sport(s) practiced, the age of start, the 
agonistic level and any other practiced sports. 
Section two collected self-report data about age of the first snus experience. The 
current snus use was asked by the question ‘‘Use snus now?’’ with answers  ‘‘no'’, 
‘‘occasionally’’ (less than once a day, defined as ‘occasional use’), or, ‘‘once or 
more a day’’ (defined as ‘regular use’) 1. Reinforcing effects of snus was 
investigated with the items: 1 “Was using snus satisfying?”, 2 “Did snus taste 
good?”, 3 “Did you enjoy the sensations in your throat and chest?”, 4 “Did using 
snus calm you down?”, 5 “Did using snus make you feel more awake?”, 6 “Did 
using snus make you feel less irritable?”, 7 “Did using snus help you concentrate?”, 
8 “Did using snus reduce your hunger for food?”, 9 “Did using snus make you 
dizzy?”, 10 “Did using snus make you nauseous?”, 11 “Did using snus immediately 
relieve your craving for a cigarette?”, 12 “Did you enjoy using snus?”. These items 
are rated on a seven-point scale ranging from 1 (not at all) to 7 (extremely) 
(Caldwell et al., 2010; Cappelleri et al., 2007). Section three investigated current 
smoking status. At the question “Do you smoke at the present?”, answers were 
“no”, “occasionally” (less than one cigarette a day, defined as ‘occasional smoking) 
and “yes” (one or more cigarette a day, defined as ‘regular smoking’).  
The number of cigarettes smoked per day was also recorded. The questionnaire 
used to collected data was the modified Cigarette Evaluation Questionnaire 
(mCEQ) 13 with 12 items: 1 “Was smoking satisfying?”, 2 “Did cigarettes taste 
good?”, 3 “Did you enjoy the sensations in your throat and chest?”, 4 “Did smoking 
calm you down?”, 5 “Did smoking make you feel more awake?”, 6 “Did smoking 
make you feel less irritable?”, 7 “Did smoking help you concentrate?”, 8 “Did 
smoking reduce your hunger for food?”, 9 “Did smoking make you dizzy?”, 10 “Did 
smoking make you nauseous?”, 11 “Did smoking immediately relieve your craving 
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for a cigarette?”, 12 “Did you enjoy smoking?”. These items are rated on a seven-
point scale ranging from 1 (not at all) to 7 (extremely). 
According to Cappelleri et al., (2007) the twelve items are grouped in five domains: 
Satisfaction with three items (items 1, 2, and 12); Psychological Reward with five 
items (items 4 through 8); Aversion with two items (items 9 and 10); Enjoyment of 
Respiratory Tract Sensations (Item 3); and Craving Reduction (item 11). Scores for 
each subscale were calculated as the average of its individual item responses. 
Higher scores indicated greater intensity of each snus/smoking effect. 
Questionnaires were administered after competitive races or during training in 
Italian Dolomites (Northern Italy) and were made anonymous by an alphanumeric 
code (2-letter name initials and 8-digit date of birth). 
In according with Italian law, in the case of administration of questionnaires to 
healthy voluntary participants, does not require the approval of the ethics 
committee. 
Data were analyzed by Mann Whitney test and unpaired t test analysis (GraphPad 
Prism 4). 
 
2.3 Results 
In Survey I among 108 participants, there were more males than females (72 vs. 
36) (Table 1). The mean age was the same for both gender subgroups, with an 
overall average value of 23.9 years (± 2.6 SD). Except for 3 participants, all were 
agonistic winter sport athletes (97.2%), with all of them starting activity at a very 
young age (5.7 ± 2.5, years of age ± SD). Ninety-two participants (85.2%) did more 
than one exercise or sport activity (e.g., cycling, running) other than the main winter 
sport (Table 1). 
Eighty athletes of the total (74%; 80.5% of males and 61.1% of females) tried snus 
at least once. Contingency table analysis shows a significant gender difference, 
with a higher risk to experience snus if male (odds ratio = 2.636 [C.I. 1.084, 6.412]; 
p = 0.037). Fifty-nine athletes had a limited past experience (ranging from 1 to 50 
times) whereas 21 took snus more than 50 times. The first snus experience took 
place at an average age of 17.3 years (± 1.9 SD), with no significant difference 
between males and females (Table 1).  
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Table 1. Survey I. STUDY I. Demographics of participant and prevalence of past 
snus experience.  
 
 Totals  [%] Male  [%] Female [%] 
Participants, N 108 [100] 72 [67.0]a 36 [33.0]a 
Age in years, mean (± SD)  23.9  (±2.6) 24.3 (±2.8) 23.3 (±1.8) 
Athletes performing agonistic winter sports, N 105 [97.2] 69 [95.8] 36 [100] 
alpine skiing 
nordic skiing 
biathlon 
83 [76.8] 
23 [21.3] 
2 [1.9] 
53 [73.6] 
17 [23.6] 
2 [2.8] 
30 [83.3] 
6 [16.7] 
0 [0.0] 
Age of starting winter sport, mean years (± SD) 5.7 (±2.5) 5.9 (±2.8) 5.4 (±2.0) 
Athletes performing supplementary exercise  
or sport activity, N 
 
92 [85.2] 
 
65 [90.3] 
 
27 [75.0] 
 
Past snus experience, N 
limited (1 to 50 times)  
extensive (≥ 50 times)   
 
80 [74.0] 
59 [54.6] 
21 [19.4] 
 
58 [80.5] 
39 [54.2] 
19 [26.3] 
 
22 [61.1] 
20 [55.5] 
2 [5.6] 
Age of first snus experience, mean years (± SD) 17.3 (±1.9) 17.3 (±2.1) 17.2 (±1.1) 
 
Values represent number of participants, except for current age, age of starting winter 
sport, and ages of first snus experience (years; mean ± SD). [%] = percentage of 
corresponding Participants column (Totals, Male or Female), except for a = percentage of 
Totals Participants value. 
 
At the time of interview, 54 participants were snus users (50% of the total) with a 
higher prevalence among the group of males (58.3% out of the total of males) 
compared to the group of females (33.3% out of the total of females). Male gender 
is a risk factor for being current snus user  (odds ratio = 2.800 [C.I. 1.213, 6.464]; p 
= 0.024). All females taking snus were occasional users (less than once use a day), 
whereas 11 out of 72 males were regular users (15.3% using snus once or more a 
day, vs. 43% of occasional snus users) (Table 2). 
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Table 2. Survey I. STUDY I. Prevalence of snus and smoke use.  
 
 Totals  [%] Male  [%] Female [%] 
Participants, N 108 72 36 
    
No current snus users, N  54 [50.0] 30 [41.7] 24 [66.7] 
Current snus users, N 54 [50.0] 42 [58.3] 12 [33.3] 
occasional  43 [39.8] 31 [43.0] 12 [33.3] 
regular  11 [10.2] 11 [15.3] 0 [0.0] 
 
No current smokers, N 
 
67 [62.0] 
 
49 [68.0] 
 
18 [50.0] 
Current smokers, N 41 [38.0] 23 [31.9] 18 [50.0] 
 
Values represent number of participants.  [%] = percentage of corresponding Participants 
column (Totals, Male or Female). 
 
Forty-one participants out of 108 were current smokers (38%) with a trend of 
gender prevalence opposite to that reported for snus: 50% of females vs. 31.9% of 
males were current smokers (odds ratio = 0.4694 [C.I. 0.2067, 1.066]; NS). The 
average number of smoked cigarette/day is low (4.4 ± 3.9 SD) with no difference 
between genders.  
In Survey II among 61 participants, there were more males than females (51 vs. 10) 
(Table 3). The mean age was 26 years (± 5.4, SD). Fifty-five participants practiced 
alpine skiing, three snowboarding, two nordic skiing and only one curling. Thirty-
three participants were agonistic athletes (54% of the total), with all of them began 
activity at 4.9 (± 3.6), years of age (± SD). Fifty-two participants (85.2%) practiced 
more than one exercise or sport (e.g., cycling, soccer) other than the main sport 
activity (Table 3). 
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Table 3. Survey II. STUDY I. Demographic of participants 
 Totals  
[%] 
Male  [%] Female 
[%] 
Participants, N 61 [100] 51 [83.6]a 10 [16.4]a 
Age in years, mean (± SD)  26  (±5.4) 26.1 
(±5.5) 
25.9 (±5.7) 
Athletes performing agonistic winter sports, N 33 [54.0] 29 [87.8] 4 [40.0] 
alpine skiing 
snowboard  
nordic skiing 
curling 
 
55 [90.2] 
3 [4.9] 
2 [3.3] 
1 [1.6] 
48 [94.1] 
3 [5.9] 
0 [0.0] 
0 [0.0] 
 
7 [70.0] 
0 [0.0] 
2 [20.0] 
1 [10.0] 
Age of starting winter sport, mean years (± SD) 4.9 (±3.6) 4.7 (±3.2) 5.6 (±5.4) 
Athletes performing other exercise or sport activity, 
N 
52 [85.2] 44 [86.3] 8 [80.0] 
    
 
[%] = percentage values of corresponding Participants column (Totals, Male or Female), 
except for a = percentage of corresponding Totals Participants value. 
 
At the time of the survey, 49 athletes were currently using snus (80.3% of the total). 
Among them twenty-five subjects were occasional snus users (19 male and 6 
female) and 24 were regular snus users (21 male and 3 female) (Table 4) 
Thirty-two athletes were current smokers (52.5% out of the total) with 27 males 
(53% out of the total of males) and 5 females (50% out of the total of females). 
Twenty-nine participants out of 61 were current smokers (47.5%) with 24 males 
(47% out of the total of males) and 5 females (50% out of the total of females) as 
shown in Table 4. 
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Table 4. Survey II. STUDY I. Prevalence of snus and smoking use. 
 
 Totals  [%] Male  [%] Female [%] 
Participants, N 61 51 10 
 
Age of first snus experience in 
years, mean (± SD) 
 
 
20.3 (± 5.7) 
 
 
19.8 (± 5.7) 
 
 
22.5 (± 4.7) 
 
No current snus users, N  
 
12 [19.7] 
 
11 [21.6] 
 
1 [10.0] 
Current snus users, N 49 [80.3] 40 [78.4] 9 [90.0] 
occasional  25 [41.0] 19 [37.2] 6 [60.0] 
regular  24 [39.3] 21 [41.2] 3 [30.0] 
 
No current smokers, N 
 
32 [52.5] 
 
27 [53.0] 
 
5 [50.0] 
Current smokers, N 29 [47.5] 24 [47.0] 5 [50.0] 
occasional  17 [27.8] 14 [27.4] 3 [30.0] 
regular  12 [19.7] 10 [19.6] 2 [20.0] 
 
Values represent number of participants.  [%] = percentage values of corresponding 
Participants column (Totals, Male or Female). 
 
The average of mCEQ score for each item reported by occasional and regular 
current snus users is shown in Table 5.  All mean mCEQ score values for each item 
were significantly different from score value = 1 (“Not at all”), thus confirming that 
snus use induced reinforcing effects. The existence of a dose-effect relationship 
between snus use and reinforcing effects was tested by comparing mCEQ score 
values for each item in occasional vs. regular users. As show in Figure 4 and in 
Table 5, a significant difference in mCEQ scores between the two levels of snus 
use was observed only for three items, that is item 1 “Was using snus satisfying?”, 
item 2 “Did snus taste good?” and item 12 “Did you enjoy using snus?”, suggesting 
that the existence of a dose-effect relationship was limited to few items. 
 
 
 
 
!! 20!
 
 
 
Figure 4. Survey II. STUDY I. Score values (mean, SE) for each mCEQ item in occasional 
and regular current snus users. Bars represent occasional (open) and regular (solid) snus 
users. Items 1 to 12 respectively represent: 1 “Was using snus satisfying?”, 2 “Did snus 
taste good?”, 3 “Did you enjoy the sensations in your throat and chest?”, 4 “Did using snus 
calm you down?”, 5 “Did using snus make you feel more awake?”, 6 “Did using snus make 
you feel less irritable?”, 7 “Did using snus help you concentrate?”, 8 “Did using snus reduce 
your hunger for food?”, 9 “Did using snus make you dizzy?”, 10 “Did using snus make you 
nauseous?”, 11 “Did using snus immediately relieve your craving for a cigarette?”, 12 “Did 
you enjoy using snus?”. *p < 0.05, **p < 0.01, ***p < 0.001,  unpaired Student t-test 
comparison between occasional current snus users versus regular current snus users for 
each item. 
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Table 5. Survey II. STUDY I. Mean (SE) score value for mCEQ items in occasional 
and regular current snus and smoke users. 
 
mCEQ 
item 
Occasional 
snus users 
(N 25) 
Regular  
snus 
users  
(N 24) 
   p value Occasional 
smoke users 
(N 17) 
Regular 
smoke users 
(N 12) 
 p value 
 
1 3.6 (0.2) 4.5 (0.3) 
   
 0.0088** 3.0 (0.4) 4.6 (0.4) 
   
  0.0084** 
2 2.9 (0.3) 4.0 (0.4)    0.0583 2.4 (0.3) 4.8 (0.4)   0.0003*** 
3 2.2 (0.2) 2.9 (0.4)    0.2521 2.4 (0.3) 4.2 (0.4)   0.0045** 
4 4.1 (0.3) 5.2 (0.3)   0.0252* 3.6 (0.4) 5.2 (0.3)   0.0094** 
5 2.6 (0.2) 2.9 (0.4)    0.9600 2.0 (0.3) 3.5 (0.4)   0.0063** 
6 2.8 (0.3) 2.7 (0.3)    0.6515 2.7 (0.3) 4.1 (0.5)   0.0177* 
7 2.8 (0.3) 3.4 (0.4)    0.2968 1.9 (0.2) 3.8 (0.4)   0.0007*** 
8 2.3 (0.3) 3.0 (0.3)    0.1663 3.6 (0.5) 3.6 (0.5)   0.9329 
9 2.8 (0.3) 2.8 (0.3)    0.8881 2.5 (0.4) 1.5 (0.2)   0.1339 
10 2.3 (0.3) 2.1 (0.2)    0.8482 1.9 (0.3) 1.3 (0.1)   0.0831 
11 2.8 (0.4) 3.5 (0.5)    0.2522 3.9 (0.5) 5.0 (0.6)   0.1750 
12 4.1 
 
(0.3) 
 
5.8 
 
(0.2) 
 
0.0001*** 3.1 
 
(0.4) 
 
5.0 
 
(0.4) 
 
  0.0012** 
 
*p < 0.05, **p < 0.01, ***p < 0.001, unpaired Student’s t-test comparison between 
occasional current users versus regular current users for each item. 
 
On the other hand, a significant difference between occasional and regular smokers 
was observed for a greater number of items, that is for items 1, 2, 3, 4, 5, 6, 7 and 
12 (see Table 5), suggesting that the quantitative subjective description of smoking 
– induced reinforcing effect could be discriminated depending to the dose (i.e., 
amount of use). 
According to Cappelleri et al (2007) groups of items could be clustered into five 
psychological domains (see Methods). As shown in Table 6 mean mCEQ score 
values where similar across domains (except for Aversion in regular smokers) thus 
suggesting that snus use – as well as smoking – induced reinforcing effect equally 
distributed across domains. Interestingly, the only significant differences for items 1, 
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4, and 12 between occasional and regular snus use (see above) correspond to the 
Satisfaction - items 1 and 12 and Psychological reward - item 4. 
 
Table 6. Survey II. STUDY I. Mean score (SE) mCEQ score values pooled into five 
domains for current snus users and smokers. 
 
Domain  Current snus user Current smoke users 
 Occasional Regular Occasional Regular 
Satisfaction 3.5 (0.3) 4.8 (0.3) 2.8 (0.2) 4.8 (0.1) 
Psychological reward 2.9 (0.3) 3.4 (0.5) 2.8 (0.4) 4 (0.3) 
Enjoyment of respiratory tract 
sensations  
2.2 (0.2) 2.9 (0.4) 2.4 (0.3) 4.2 (0.4) 
Craving reduction 2.8 (0.4) 3.5 (0.5) 3.9 (0.5) 5 (0.6) 
Aversion 2.5 (0.3) 2.5 (0.4) 2.2 (0.3) 1.4 (0.1) 
 
Satisfaction = items 1, 2, and 12; Psychological Reward = items 4, 5, 6, 7 and 8; Enjoyment 
of Respiratory Tract Sensation = item 3; Craving Reduction = item 11; Aversion = items 9 
and 10. 
 
2.4 Discussion 
This report describes an unexpected phenomenon of snus use in a sample of 
winter sport athletes in Italy. This segment of snus user population was 
characterized by healthy, young athletes performing more than one sport, full-time 
involved in training and competitive winter sport activities (mostly Alpine and Nordic 
skiing) since the time of their childhood. Moreover, the survey was conducted in an 
European country where there is not socio-cultural tradition and marketing of snus. 
When a different sample of winter sport athletes were asked to rate snus reinforcing 
effects (Survey II), it emerged that snus use induced reinforcing effects similar to 
smoking tobacco, and that some of these effects – those associated to reward and 
satisfaction - were positively related to snus daily intake (occasional vs. regular). 
On Survey I, an average of three-quarter of the participants reported past 
experience with snus. Fifty-five participants were current snus users, most of them 
with an occasional pattern of administration (less than once a day), whereas about 
10% of the participants were regular users. Data from Survey I were also confirmed 
in Survey II: as expected the prevalence of current snus users was higher in the 
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latter (80.3 vs. 50%) because the participants selection criteria (to have a past or 
current status of snus user).  
This prevalence among an athlete population is not surprising. Since ’80s and ‘90s, 
anecdotal and literature reports showed that young people involved in sport 
activities were users of smokeless tobacco (Glover et al., 1986; Glover et al., 1988; 
NCAA 1989). U.S. surveys among college athletes reported prevalence of 
smokeless tobacco use ranging between 30 and 40% (Connolly et al., 1988; 
Ernster et al., 1990; Severson et al., 1998). Walsh and colleagues (Walsh et al., 
1994; Walsh et al., 2000) have extensively investigated the phenomena of spit 
tobacco among baseball players. Interestingly, Davis et al., (1997) showed that 
smokeless tobacco use among high school male students was correlated to athletic 
activity, and that sport participation was a predictor of such as use. To our 
knowledge, published reports about snus use among winter sport athletes are few 
(Bujon 2008; Schweizer et al., 1998). A recent analytical chemistry study confirmed 
that ice hockey players take relevant amounts of nicotine through smokeless 
tobacco (Marclay and Saugy 2010). Marclay and colleagues (2011), by using 
analytical chemistry detection, assessed smokeless tobacco use in athletes from 
various sports by measuring nicotine and metabolites levels.  
Our survey was limited by the small sample size, due to the limited dimension of 
this specific segment of the population. The number of participants that agreed to 
be interviewed was also limited by the fact that the survey was conducted in 
proximity of competitions when some athletes refused to participate because the 
concomitant sport event.   
On Survey II, the findings showed that snus induced a series of reinforcing effects. 
All the data were significantly different from score value = 1, that is “Not at all” 
effect. It was found interesting to test the possible relationship between mCEQ 
score value and snus daily use. The comparison between the two levels of intake 
(occasional vs. regular snus use), showed a significant difference for items 1, 4 and 
12. Interestingly, these items account to Satisfaction (items 1 and 12) and 
Psychological reward (item 4) domain sub-scales. Satisfaction and Psychological 
reward subscale were those with higher reliability among the five domains, and 
were moderately and positively correlated (Cappelleri et al., 2007). 
The inclusion in Survey II of the same assessment for reinforcing effects of smoking 
gave an indicative comparison between snus and smoking effects. It is evident that 
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although occasional smokers did not report score values significantly different from 
occasional snus users, regular smoking induced however a greater reinforcing 
effect as it is shown by higher mCEQ scores. Significant differences between 
occasional and regular smoking score values were shown for 8 out 12 mCEQ items 
vs. 3 out of 12 for snus. Although both snus and smoking is a delivery of nicotine, 
the degree of nicotine dependence was not measured in our study. It will be 
therefore important to further explore the nicotine dependence component of snus 
use in these participants, by also taking in consideration environmental factors 
(e.g., the sport context) in order to build a more comprehensive hypothetical 
framework that could explain snus use in sports.  
There are currently unanswered questions, such as the nicotine dependence 
degree, and about the interaction between nicotine effects and the psycho-
physiological performance under competition. According to previous literature data, 
it could be speculated that socio-cultural and/or psychobiological factors plays a 
role in initiation and maintenance of this habit. Italian winter sport athletes are 
involved in a series of winter sport competitions at a closer contact with a 
successful role-model (Wiium et al., 2009; Gottlieb et al., 1993), such as that 
offered by those North American and North European athletes using snus. It is also 
possible that the sport environment in general may facilitate the availability of snus, 
as reported in previous studies (Huhtala et al., 2006; Karvonen et al., 1995).  
In conclusion, this survey confirms a high prevalence of snus use among winter 
sport athletes. At present, there are no data that could warn against such as use as 
detrimental for sport performance, or as a form of doping. On the other hand, risks 
associated to snus-contained carcinogenics are well-known (ESTOC 2008). 
Although there is consensus that the health risks of smoking are much greater than 
those of snus, it is however important to increase information and education among 
this segment of young athletes. 
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3. STUDY II 
Effects of snus administration on exercise endurance in men 
 
3.1 Introduction 
Snus is a smokeless tobacco consumed orally, not smoked, traditionally produced 
and used in Sweden (Rutqvist et al., 2011). It is typically placed between the upper 
lip and the gum for approximately 30 min before it is discarded. Sweden is the only 
country in the EU granted special exemption to manufacture and snus sales (Anon 
1992; Ahlbom et al., 2007; Fagerström and Schildt 2003). In 2006, snus was 
introduced in USA and Alpert and colleagues (2008) reported a increasing trends 
in its use.  
Zandonai et al (2013) reported an increase snus use among alpine skiers in 
northern Italy. An analytical chemistry study confirmed that ice hockey players take 
relevant amounts of nicotine through smokeless tobacco (Marclay and Saugy 
2010). More recently, Marclay and colleagues, by using analytical chemistry 
detection, assessed smokeless tobacco use in athletes from various sports by 
measuring nicotine and metabolites levels (Marclay et al., 2011). On 2012, 
nicotine has been placed on WADA’s 2012 Monitoring Program (WADA 2012) in 
order to detect potential patterns of abuse.  
There are however unanswered questions about sought and subjective reinforcing 
effects experienced by this specific athletic population. In fact, from a 
psychobiological standpoint, snus is a delivery of a psychoactive and addictive 
substance, nicotine (Henningfield et al., 1997; Fagerström et al., 2011).  
Only few experiments have been performed to test human performance under the 
effect of smokeless tobacco, and none on snus. In particular, Mundel and Jones 
(2006) have shown that nicotine administered through the skin (patch), increased 
the duration of an endurance performance but not the perception of fatigue when 
compared to a placebo condition. Authors concluded that nicotine prolonged the 
endurance performance throughout a central mechanism. Indeed, there are 
different ways to measure the effect of fatigue at a cognitive-perceptual level: one 
is to consider the subjective intensity of effort, strain, discomfort, experienced 
during a physical exercise (Robertson and Noble 1997) whereas the other is the 
neuro-physiological discrimination from two different sources, one peripheral and 
one central (Enoka and Stuart 1992; Gandevia 2001).  
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Therefore, the aim in this study to investigate the snus effects on exercise 
endurance correlated with the perception of fatigue along with a range of 
physiological and neuro-physiological parameters. We predict that administration 
of snus during exercise at 65% Wmax until exhaustion, will confirm Mundel and 
Jones’s results described above. 
 
3.2 Materials and Methods 
3.2.1 Participants 
We recruited 14 healthy males (18 to 65 years) volunteers non-smokers and non-
snus users. The exclusion criteria were the presence of symptomatic cardiopathy, 
metabolic disorders such as obesity (BMI >30) or diabetes, chronic obstructive 
pulmonary disease, epilepsy, therapy with beta-blockers and medications that 
would alter cardiovascular function, hormonal therapy, alcoholism and smoking. 
 
3.2.2 General Design 
All participants were submitted to a medical visit (MD) and they were informed 
about the procedures and risks and they signed an informed consent form at the 
end of the MD. 
The institutional review board of the Department of Neurological, 
Neuropsychological, Morphological and Motor Sciences, University of Verona, 
approved the study protocol, the experimental design and methods that conformed 
to the 1964 Declaration of Helsinki. 
The protocol consists of three experiments carried on an electrically braked cycle-
ergometer (Sport Excalibur, Lode, The Netherlands) set in the pedal rate 
independent mode. Experiment 1 (EXP1): an incremental exercise test to 
determine maximal aerobic power output (Wmax). Experiment 2 (EXP2) and 
experiment 3 (EXP3) involve exercising at 65% Wmax until exhaustion and 
Swedish snus (SS) or Swedish snus placebo (SP) was administered to 
participants at the start exercise (EXP2 and EXP3). Before and after all 
experiments participants were administered the Profile of Mood of State 
questionnaire (POMS) and tested with Transcranial Magnetic Stimulation (TMS) to 
check changes in cortico-motor excitability due to the prolonged exercise. The 
study was a double-blind crossover design study comparing the effect of SS vs. 
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SP on exercise endurance. A MD was conducted in the same day of the EXP1 
and after three days all participants were attended EXP2. EXP3 began at least 
one week apart EXP2. Participants were randomized to blindly receive SS or SP 
on EXP2 day and on EXP3 day. 
 
3.2.3 Protocol 
Participants arrived at the School of Exercise and Sport Sciences, University of 
Verona, by 08.30 a.m., wearing cycling shorts and socks.  
 
LAP (Laboratory Action Perception) session. Participants were accompanied into 
the LAP where it was administered the POMS questionnaire. Participants read the 
questions on the monitor and answered with the aid of a numeric keyboard. Then, 
the TMS session was carried out. The optimal scalp position (OSP) over the left 
primary motor cortex for eliciting motor evoked potentials (MEPs) was selected to 
record stable MEPs from two lower leg muscles (Tibialis Anterior (TA) and Vastus 
Lateralis (VL) (First dorsal Interroseous (FDI) as a control)). During the recording 
session the coil position was over the left motor cortex, in correspondence with the 
OSP. The resting motor threshold (rMT) was defined as the lowest stimulus 
intensity able to evoke 5 out of 10 MEPs with amplitude of at least 50 µV in the VL. 
Twenty transcranial stimuli (TMS20) were delivered to the relaxed muscle at a 
stimulus intensity of 1.2 × motor threshold (MT), in order to investigate MEP 
characteristics such as peak-to-peak amplitude and latency at a standardized 
intensity (Verin et al., 2004). After these measurements we connected S-Beam 
Load Cell (DBBSE), securely strapped into the floor, to the dominant limb ankle to 
maximum voluntary contraction (MVC). Participants were performed six brief (3s) 
control MVCs of the Vastus Lateralis (VL), from which peak torque and peak 
surface EMG was measured. Six peripheral stimuli were then delivered to the 
relaxed muscle.  
 
Exercise Physiology Lab session. EXP1. The participants performed on a cycle-
ergometer the first incremental sub maximal test, in order to get a considerable 
workload-V’O2 relation. The incremental ramp exercise protocol, preceded by 6-
min of rest, consisted in cycling on a workload which increased by 30 W every 6 
min. The initial workload was 0W and the last step was 150W, pedal frequency 
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was held constant at 75 rpm. After 30 min of rest and rehydration a second test 
was performed, as reported below. 
The incremental exercise test workload initial was 50 W, which increased by 25 or 
35 W every 1 min until voluntary exhaustion. The latter was defined as the inability 
to maintain the pedaling frequency (60 – 80 revolutions/min (rpm)), despite 
vigorous encouragement by the experimenters. Heart rate (HR) was monitored 
continuously as well as expiratory minute ventilation (V ̇E), O2 consumption rate 
(V ̇O2) and rate of CO2 production (V ̇CO2), from which the respiratory exchange 
ratio (RER). The test was considered maximal if one of the following criteria was 
met: (1) final HR was within 10% of predicted maximum; (2) a clear plateau in 
oxygen uptake was noticed; or (3) respiratory exchange ratio will be equal to, or 
above, 1.10 (ACSM 2009). Global rating of perceived exertion (RPE) was 
recorded in the last 15 s of each exercise new incremental step and was recorded 
using the 15-point Borg scale (Borg 1982a). Maximal aerobic power output was 
identified as the intersection point between individual relations of V’O2 to W’ (from 
the first test) and the V’O2 max value (from the second test).  
At the end of the EXP1, participants were accompanied into the LAP for TMS20 
and MVC experiments and POMS questionnaire, in this order. 
 
EXP2 and EXP3. Participants were asked to record, in a specific table sent by 
mail, their diet in the 24 h period before the EXP2 and were instructed to follow the 
same diet before each subsequent experiment. They had to abstain from physical 
activity, alcohol and caffeine consumption. The measurement of exhaled carbon 
monoxide (CO) level was performed using the EC50 Micro Smokerlyzer† (Bedfont 
Scientific Ltd.). During the exercise at 65% Wmax until exhaustion were 
continuously measured: i) stroke volume of the heart and cardiac output by means 
of cardio-impedance; ii) pulse pressure profile, mean, systolic, diastolic pressures 
by means of photoplethysmography: iii) muscle and cerebral oxygenation by 
means of NIRS (near-infrared spectroscopy) (Perrey 2008). The muscular NIRS 
lightweight plastic probe was longitudinally positioned on the belly of the VL 
muscle 15 cm above the patella and attached to the skin with a bi-adhesive tape. 
The cerebral NIRS lightweight plastic probe was positioned on the frontal side, the 
same of the dominant leg, and attached to the skin. Arterial pressure profile was 
continuously recorded at a fingertip by using a non-invasive 
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photoplethysmographic method. Participants remained stationary on the cycle-
ergometer for 5 min to acquire baseline measurements. Blood samples were taken 
at time -3 min to determine the blood lactate concentration ([La]b mM), blood 
glucose concentration ([G]b mM) and ([Hb]b, g). In the last 10 sec they took the 
sachets of SS or SP from the box. They placed in the anterior part of mouth 
between the upper gingiva slightly pulling the mask (Time zero = T0). The 
participants had to keep in their mouth the SS or SP until the end of the exercise. 
Immediately after they started pedaling with a frequency around 75 rpm/min for 5 
min (warm up). The load in warm-up was (means ± SD) of 100 ± 50 W and it was 
calibrated on EXP1 for each subject. Global rating of perceived exertion (RPE) 
was recorded in the last 15 s of each 5 min until the end of the test. RPE was 
recorded using the 15-point Borg scale (Borg 1982). Blood samples to determine 
the blood lactate concentration ([La]b mM), blood glucose concentration ([G]b mM) 
and ([Hb]b, g) were taken each 10 min from T0 until the end of the test. At the end 
of warm-up started the exercise at 65% Wmax until exhaustion with a load 
calibrated on EXP1 for each subject. In figure 5 a schematic representation of the 
protocol and its measurements. 
 
 
Figure 5. STUDY II. Schematic representation of the protocol and its measurements in 
minutes. Abbreviations: SS/SP: Swedish snus or Swedish snus placebo; RPE: Rating 
perception of effort (Borg’s scale). 
!! 30!
At the end of the exercise at 65% Wmax participants spat out snus. Immediately 
we performed an interview to participants about nicotine adverse events (if yes: 
mild / moderate/ serious). Participants were taken 5 ml of blood to nicotine and 
cotinine measurements. At the end of the physiological lab sessions the 
participants were accompanied into the LAP where were administered TMS20 and 
MVC experiments and POMS questionnaire in this order. 
 
3.2.4 Materials  
Snus  
Swedish snus according to the GothiaTek standard is a low-nitrosamine, moist 
oral tobacco product with water content of approximately 45%–55% and a pH of 
approximately 8.5. Lunell and Lunell (2005) described nicotine delivery and uptake 
from snus sachets. The mean time to maximum nicotine plasma concentration 
(Tmax) is 37.1 ± 10.2 (SD) min (range: 24–60 min) for 1 g Swedish portion snus 
(Lunell and Curvall 2011). Fagerstrom et al (2012) show a lack of serious AEs that 
require medical intervention.  The placebo was almost identical to the snus in 
physical appearance, mouth feel, pH, flavouring, and other sensory 
characteristics, but it did not contain tobacco or nicotine. The placebo is composed 
of water, oat and cocoa fibers, humectant (E422), flavor enhancer (sodium 
chloride), acidity regulator (E504, E500) and aromas. In this study were 
administrated a commercial Catch White Eucalyptus Portion Snus (Swedish 
Match) 1.0 g for SS and Onico Pepparmint  (Swedish Match) 1.0 g for SP 
respectively.  
 
POMS questionnaire  
The POMS has been used extensively for the assessment of mood in the sport 
and exercise environments. This questionnaire has 58 items and the factor 
structure representing six dimensions of the mood construct: Tension, Depression, 
Anger, Vigor, Fatigue and Confusion. Items were answered on a 5-point Likert 
scale (0 = not at all, 1 = a little, 2 = moderately, 3 = quite a bit, 4 = extremely). Raw 
scores were transformed following the standard point table  (McNair et al., 1991).  
 
The DBBSE series S-beam load cell 
The DBBSE series S-beam load cell (Applied Measurements Ltd., Berkshire, UK) 
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is designed for force measurement and weighing applications alike. 
Characteristics’ cell load are: capacities: 0-1kg up to 0-100; output: 2.0 ± 0.1mV/V; 
high accuracy: < ± 0.03%/RC. Force was transmitted, amplified, and displayed on 
a personal computer running Spike2 software, via a CED 1401 data logger 
(Cambridge Electronic Design Ltd., Cambridge, UK). 
 
Transcranial Magnetic Stimulation (TMS)  
TMS was performed by using a 70-mm figure-of-eight coil connected to a Magstim 
200 Rapid (Magstim, Whitland, Dyfed, UK), producing a maximum output of 2 T at 
the coil surface (pulse duration, 250 msec; rise time, 60 msec). Muscle activity 
was recorded and amplified with a Digitimer D360 8-channel and CED Power 
1401 (Digitimer, Hertfordshire, England), band-pass filtered (20 Hz–3 kHz) and 
sampled at 5 kHz. Electromyographic activity was recorded with surface 
electrodes over TA, VL and FDI muscles. TMS stimuli sequences were processed 
by the Psychology Tools' Eprime2 software (Pittsburgh, PA). 
 
Maximal Voluntary Contraction  
We have computed the MVC averaging 20 ms before the TMS pulse and we 
chose the best over six. We calculated the percentage of the condition post in 
relation to the condition pre. Moreover we measured the peak twitch tension after 
TMS and we averaged the 6 trial performed during the MVC and the 6 recorded at 
rest. We calculated the percentage of the condition post in relation to the condition 
pre. TMS data. For the TMS we computed the peak-to-peak amplitude of each 
MEP then, we eliminated the MEPs ± 2 standard deviations and finally, the 
average was computed. 
 
Smoking status and cotinine level  
The measurement of exhaled CO concentration, a non-invasive method of 
assessing smoking status, was measured using the EC50 Smokerlyser (Bedfont 
Instruments; Kent, UK). Bedfont EC50 analyzer is reported to correlate closely 
with blood carboxyhaemoglobin concentration in smokers and in non-smokers. 
The Smokerlyser measures breath CO levels in parts per million (ppm) based on 
the conversion of CO to carbon dioxide (CO2) over a catalytically active electrode 
(Middleton and Morice 2000). Venous blood sample (5 ml) were collected into pre-
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chilled EDTA-containing tubes. The blood was centrifuged at 2300 g for 12 min at 
4°C and the plasma separated and stored at -20° C for nicotine and cotinine 
analysis.  
 
Chemical and reagent 
Nicotine, cotinine and acetanilide (internal standard: IS) were purchased from 
Sigma-Aldrich (Milan, Italy). Acetonitrile, dichloromethane, sodium hydroxide and 
ammonium acetate (Merck KgaA - Darmstadt, Germany); formic acid and 
hydrochlorid acid (Sigma-Aldrich - Milan, Italy) were analytical-reagent grade, 
milliQ water was filtered and deionised with Ultra Pure Water System, MilliQ-plus 
(Millipore, USA). 
 
Chromatographic analysis 
Nicotine, cotinine and acetanilinide (IS) were determined by means of an HPLC 
technique coupled with MS detection. Analytes were separated on a Restek Ultra-
C8 column (150 mm X 2.1 mm - 5 µm) (USA) at a flow-rate of 0.2 ml min-1. 
Separation was carried out in isocratic conditions with a solution of 
acetonitrile/water/formic acid + 2 mmol l-1 ammonium acetate (78/22/0.1 v/v).  
Chromatographic equipment consists of High Performance Liquid 
Chromatography (HPLC) LC-200 pump; samples were detected in Selected Ion 
Monitoring (SIM) (m/z nicotine m/z 163.1, cotinine 177.1 and acetanilide 136.0) 
with positive electrospray ionisation (ESI), by a Q-trap LC/MS/MS Systems (MDS  
Sciex - Ontario, Canada). Data were acquired and processed with Analyst 1.4. 
(Applied Biosystems package, MDS Sciex - Ontario, Canada). The system 
operated at room temperature. In these conditions nicotine, cotinine and 
acetanilide retention times were 2.38, 2.45 and 2.78 minutes respectively.  
 
Calibrators and quality control samples 
Calibrators and control samples containing nicotine and cotinine were prepared 
adding known amounts of analytics to blank serum. They were included in each 
batch of volunteers’ samples. Calibration curves and quality control samples 
ranged respectively, from 2 to 50 and 3 to 15 ng ml-1 for nicotine and from 20 to 
500 and 30 to 150 ng ml-1 for cotinine. Limit of detection (LOD) for nicotine and 
cotinine were 2 and 20 ng mL-1 respectively. 
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Sample preparation  
To purify nicotine and cotinine from serum samples, we modified the extraction 
procedure proposed by Nakajima et al (2000); extraction was a simple two steps 
procedure: alkalinisation and organic extraction. One ml of serum was transferred 
to a polypropylene tube, followed by addition of 50 µl of internal standard 
(acetanilinide 10 ng µl-1) and 50 µl of sodium hydroxide (10M). The tubes were 
vortexed and samples extracted with 8 ml of dichloromethane by rotation for 10 
minutes and centrifuged at 3000 RPM for 10 minutes. The organic layer was 
transferred to a glass tube containing 50 µl of hydrochlorid acid (37%). After 
evaporation of the organic phase, under a nitrogen stream at 40°C, the residue 
was dissolved with 75 µl of mobile phase and 20 µl was injected into the HPLC 
system. 
 
Physiological measurements  
Breath by breath gas exchanges and heart rate (HR) were measured using 
metabolic cart (Quark b2, Cosmed, Italy) during all experiments. NIRS is a non-
invasive technology that makes it possible to continuously monitor the changes 
(either relative or absolute) in oxy- (O2Hb), deoxy- (HHb), total Hb (THb) and 
myoglobin (Mb) concentrations, during a dynamic exercise (Mancini et al., 1994).  
Heart stroke volume (SV) was determined on a beat-by-beat basis by means of 
the Modelflow method, applied off-line to the pulse pressure profiles using the 
Beatscope software (Portapres, FMS, Amsterdam, The Netherlands). 
 
Blood sample 
The blood lactate concentration ([La]b, mM) and blood glucose concentration 
([G]b, mM) in arterialised capillary blood was assessed by means of an electro-
enzymatic method (Biosen C_line, EKF Diagnostic, Barleben, Germany) on 10 ll 
blood samples taken from an earlobe. The blood hemoglobin concentration ([Hb]b, 
g) in arterialized capillary blood was assessed by means of HemoCue® Hb 201+, 
Hemocue AB, Ängelholm, Sweden. 
 
Data analysis 
Times to exhaustion data were analyzed using a paired Student’s t-test (SS vs. 
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SP). RPE data were analyzed using a paired Student’s t-test (SS vs. SP). POMS 
data were analyzed using ANOVA two-way test (pre/post – SS/SP). For the MVC, 
muscle twitch and TMS were analyzed using a full within ANOVA test (SS vs. SP). 
Then, to compare the condition post with the condition pre an one sample t-test 
was used with an alternative hypothesis not equal to 100. The normality and 
homogeneity of the variance were tested using the Shapiro-Wilk normality test and 
the Bartlett test of homogeneity of variances. For the data that did not have 
homogeneity of variance, the data were log transformed and a Welch one-way 
ANOVA was used. Statistical significance will be accepted at P < 0.05. 
 
3.3 Results 
Participants 
Fourteen participants were recruited and one subject withdrew from the study for a 
leg injury at the end of EXP2. Participants’ characteristics were (means ± SD): 
age, 22.8 ± 4.6 years; height 177.3 ± 6.1 cm; VO2 max, 48.9 ± 6.4 ml kg
-1 min-1; 
Wmax, 205.7 ± 46.2 W; HRmax, 181 ± 9 beats min-1. The weight in EXP1 was 73.9 
± 7 kg, while in SS test and in SP test was 74.1 ± 7 kg and 73.8 ± 7.2 kg 
respectively. Three participants practiced soccer, three running, two tennis and the 
remaining practiced gymnastic, gym, basket, mixed martial arts (MMA) and 
swimming.  
 
Smoking status assessment and nicotine/cotinine levels 
The level of CO (ppm) was (means ± SD) 0.9 ± 0.5 before to start SS test and 1 ± 
0.9 before to start SP test. Values defined the participants as non-smokers, in 
accordance to Deveci et al (2004). The blood sampling has been carried out (time 
from participants spat out) (means ± SD): 5.2 ± 2.2 min for SS test and 6.4 ± 2.6 
min for SP test from the end of exercise. Detected plasma nicotine level was 7.31 
± 1.78 ng/ml (means ± SD) in 7 participants for SS and 3.26 ± 0.12 ng/ml (means 
± SD) in 3 participants for SP. In three participants nicotine and cotinine were no 
detectable.  
 
Adverse events 
Five participants reported adverse events at the end of SS experiment. One 
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subject reported a mild discomfort in the throat and another one a mild nausea and 
dizziness. A moderate nausea and dizziness was highlighted from two 
participants.  
 
Exercise capacity and perceived exertion 
For all participants, the average time to exhaustion was 60.4 ± 41.5 min during SS 
session and 48.8 ± 19.4 min during SP session, a +18.6% increase but not 
significant at paired Student’s t-test (P value 0.644) as show in Figure 6.  
 
 
Figure 6. STUDY II. Mean time to exhaustion for all participants. Mean time to exhaustion 
(min; ± SD) in all participants during SS   and SP ! test (n=13). 
 
Seven out 13 participants cycled for longer during the SS tests (figure 7).   
 
 
Figure 7. STUDY II. Exercise times (min) for individual subject during SS and SP test 
(n=13). 
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One subject was discarded because his time to exhaustion was insufficient to 
acquire four Borg scale values at least. RPE values at 25%, 50%, 75% and 100% 
time to exhaustion increased during both test; no differences were observed 
between each interval time in % and two conditions (placebo vs. nicotine) in paired 
Student’s t-test (figure 8).  
 
 
Figure 8. STUDY II. Borg scale values at 25%, 50%, 75% and 100% time to exhaustion. 
Borg values (mean ± SD) during SS   and SP ! test (n=13). 
 
Perceived exertion (Borg scale values) showed no significant difference (P values 
0.2031) in paired Student’s t-test during the first 30 minutes of the time to 
exhaustion (figure 9).  
 
!
Figure 9. STUDY II. Borg scale mean values in the first 30 minutes time to exhaustion. 
Mean values (± SD) during exercise for SS ☐ and SP ! test (n=12).  
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POMS 
The POMS questionnaire was measured pre and post for all experiments. Table 7 
show significant differences for Anger, Vigor and Confusion factors in pre and post 
administration for all experiments and Fatigue factor for SS; no differences were 
observed for Tension and Depression factors. In ANOVA two-way test (pre/post – 
SS/SP) no differences significant were observed. 
 
Table 7. STUDY II. Mean ± SD POMS scores in SS and SP condition. 
 
Pre: pre exercise test; post: post exercise test. *P < 0.05, **P < 0.01, ***P < 0.001, paired 
Student’s t-test (° normally distribution) comparison between pre exercise and post 
exercise in each experiment for six factors. 
 
MVC response 
The MVC was measured pre and post for all experiments and the data are 
reported in Table 8. The ANOVA did not show any difference between the SS and 
SP condition F (1,12) = 0.006, P = 0.937, while one-sample t-test showed a 
significant difference between the measurement pre and post in both conditions 
(SS t = -3.480, df = 12, P = 0.004 and SP t = -4.714, df = 12, P < 0.001; (Figure 10 
left panel)). 
The analysis of the muscle peak twitch generated by the TMS during the MVC did 
not show any difference between the SS and SP condition F (1,12) = 0.003, P = 
0.956, while the one-sample t-test showed a significant difference between the 
measurement pre and post in both conditions. SS t = -3.661, df = 12, P = 0.003 
and SP t = -5.092, df = 12, P < 0.001 (Figure 10 left panel). 
 SS SP 
POMS factors pre  post     p value pre  post     p value 
Tension 40.4 ± 3.8 39.5 ± 4.7 0.3661 40.3 ± 3.9 40.2 ± 4.7 0.7381 
Depression 43.2 ± 3.2 43.2 ± 2.5 0.3828 42.8 ± 2.9 43.3 ± 2.4 0.2165 
Anger 43.5 ± 5.8 47.2 ± 2.8 0.0103* 41.8 ± 2.2 48.2 ± 2.7 <0.0001*** 
Vigor 50.8 ± 8.1 33.4 ± 3.7 °<0.0001*** 52.7 ± 7.5 33.5 ± 3.2 <0.0001*** 
Fatigue 45.5 ± 9.1 50.8 ± 6.8 0.0332* 45.9 ± 7.5 50.8 ± 6.2 0.0620 
Confusion 43.2 ± 5.1 35.7 ± 3.6 0.0012** 42.3 ± 4.4 36.4 ± 3.1 0.0038** 
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The Welch one-way ANOVA of the muscle peak twitch generated by the TMS at 
rest did not show any difference between the SS and SP condition (Table 8), F 
(1,12) = 0.5691, P = 0.4618, while the one-sample t-test showed a significant 
difference between the measurement pre and post only in the SS conditions. SS t 
= 3.123, df = 12, P = 0.009 and SP t = 2.041, df = 12, P = 0.064 (Figure 10 left 
panel). 
 
Table 8. STUDY II. Mean ± SD of the MVC and TMS. 
SS  SP  
  Mean ± SD Δ (Pre-Post)   Mean ± SD Δ (Pre-Post) 
MVC 87.00 ± 13.5% -13.0% *  86.60 ± 10.2% -13.4% * 
PTMVC 86.60 ± 13.5% -13.4% *  86.40 ± 9.7% -13.6% * 
PTREST 103.90 ± 4.5% 3.9%   106.50 ± 11.5% 6.5%  
MEPVL 86.50 ± 38.7% -13.5% *  77.10 ± 36.9% -22.9% * 
MEPTA 103.10 ± 51.7% 3.1%     93.70 ± 45.3% -6.3%   
 
In the table are reported the mean ± the standard deviation (SD) and the difference 
between the condition pre and post (Δ(Pre-Post)). * P<0.05  
Abbreviations: MVC: maximal voluntary contraction, PTMVC: Peak twitch generated by 
the TMS during the MVC; PTREST: Peak twitch generated by the TMS at rest; MEPVL: 
Motor evocated potential Vastus Lateralis; MEPTA: Motor evocated potential Tibialis 
Anterior.  
 
TMS response 
The TMS has been applied pre and post for all experiments and the results are 
reported on the Table 8. The ANOVA of the VL MEPs did not show any difference 
between the SS and SP condition F(1,11) = 0.505, P = 0.492. One sample t-test 
showed none significant difference between the measurement pre and post in the 
SS condition t = -1.206, df = 11, P = 0.253 and close to be significant in the SP 
condition t = -2.152, df = 11, P = 0.054 (Figure 10 right panel). 
The analysis of the TA data did not show any difference between the SS and SP 
condition F(1,2) = 0.218, P = 0.650. Moreover, also the one-sample t-test did not 
reveal a difference between pre and post condition. SS t = 0.207, df = 11, P = 
0.840 and SP t = -0.482, df = 11, P = 0.640 (Figure 10 right panel). The FDI as 
control muscle did not show any activation after TMS. 
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Figure 10. STUDY II. Force cell and TMS values in SS and SP condition. The panel on 
the left shows the results obtained by the force cell in the condition SS and SP and the 
variation respect to the condition Pre (dash line) of the maximal voluntary contraction 
(MVC), Peak twitch generated by the TMS during the MVC (PTMVC) and the Peak twitch 
generated by the TMS at rest (PTREST). The panel on the right shows the results of the 
TMS in the condition SS and SP and the variation respect to the condition Pre (dash line) 
of the muscle Vastus Lateralis (VL) and Tibialis Anterior (TA). 
 
Cardiovascular and respiratory responses 
Metabolic and cardiovascular results are reported at 25%, 50%, 75% and 100% 
time to exhaustion in Table 9 for thirteen participants. Values are slightly modified 
during both test; no differences were observed between the two conditions (SP vs. 
SS) in paired Student’s t-test. Mean arterial pressure (MAP) at exhaustion 
decrease significantly in SS, P <0.05. 
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Table 9. STUDY II. Metabolic and cardiovascular results at 25%, 50%, 75% and 
100% time to exhaustion 
 
Metabolic  
parameters 
Condition 
 
25% 
 
50% 
 
75% 
 
100% 
 
V ̇E SS 76.63±17.51 81.37±21.26 87.15±25.04 93.17±26.43 
 SP 74.95±22.56 84.22±24.31 87.09±26.55 89.84±26.64 
V ̇O2 SS 2.63±0.52 2.73±0.47 2.80±0.50 2.85±0.42 
 SP 2.62±0.57 2.79±0.60 2.85±0.61 2.92±0.55 
V ̇CO2 SS 2.77±0.50 2.79±0.42 2.79±0.45 2.75±0.33 
 SP 2.76±0.54 2.83±0.53 2.80±0.55 2.82±0.47 
RER SS 1.06±0.05 1.03±0.05 1.00±0.04 0.97±0.04 
  SP 1.06±0.05 1.02±0.05 0.99±0.04 0.97±0.05 
Cardiovascular 
parameters 
MAP SS 114.49±13.90 109.90±7.34 105.14±8.15 96.76±10.02* 
 SP 110.94±16.23 106.09±13.99 108.71±8.48 108.47±8.80 
HR SS 136.89±25.65 157.25±13.37 162.26±11.21 161.68±12.72 
 SP 124.70±30.75 150.42±14.09 159.18±10.24 161.80±10.85 
C ̇O SS 17.53±3.80 20.19±2.70 19.59±2.50 17.97±3.20 
 SP 15.15±4.59 18.07±4.28 19.19±2.36 18.84±2.94 
TPR SS 0.42±0.13 0.34±0.06 0.33±0.06 0.34±0.06 
  SP 0.49±0.16 0.38±0.10 0.35±0.04 0.36±0.07 
 
Mean ± SD for each experimental condition SP and SS are reported. Statistical significant 
difference is set by *P < 0.05. Expiratory minute ventilation (V ̇E), oxygen consumption 
rate (V ̇O2), CO2 production rate (V ̇CO2), all reported in [l/min], respiratory exchange 
ratio (RER) [number]. Mean arterial pressure (MAP) [mmHg], heart rate (HR) [bpm], 
cardiac output (C ̇O) [l/min], total peripheral resistance (TPR) [mmHg.s/ml]. 
 
Muscular and cerebral NIRS responses  
Muscular and cerebral NIRS results are reported at 25%, 50%, 75% and 100% 
time to exhaustion in Table 10 for thirteen participants. Values are slightly modified 
during both test; no differences were observed between the two conditions (SP vs. 
SS) in paired Student’s t-test. 
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Table 10. STUDY II. NIRS muscular oxymetry and NIRS cerebral oxymetry values 
at 25%, 50%, 75% and 100% time to exhaustion. 
 
Nirs 
muscular 
oxymetry 
Condition 
 
25% 
 
50% 
 
75% 
 
100% 
 
Sat SS 64.20±9.86 66.75±9.17 68.83±9.23 67.92±9.14 
 SP 63.46±8.48 64.68±11.05 65.31±11.93 66.03±11.20 
THb SS 110.67±43.75 113.53±43.02 114.36±38.92 111.30±37.27 
 SP 110.01±41.62 108.06±37.56 106.75±33.71 105.93±33.78 
O2Hb SS 68.48±24.24 73.12±23.55 76.29±20.94 73.01±18.22 
 SP 68.06±22.13 67.32±18.41 67.03±14.76 67.67±16.55 
HHb SS 42.19±22.24 40.41±21.55 38.07±20.40 38.29±21.02 
  SP 41.94±22.88 40.74±23.55 39.72±23.40 38.27±21.68 
Nirs cerebral 
oxymetry 
Sat SS 52.26±9.82 53.06±9.03 54.06±8.98 54.20±9.48 
 SP 54.10±7.26 57.02±9.42 57.02±8.80 57.42±9.80 
THb SS 56.57±13.63 57.57±14.95 57.67±14.34 57.54±14.25 
 SP 54.85±11.27 56.71±12.85 57.07±14.66 57.55±15.61 
O2Hb SS 30.33±11.19 31.36±11.61 32.05±11.59 32.14±11.89 
 SP 30.37±9.69 33.38±12.21 33.68±13.02 34.23±13.67 
HHb SS 26.25±5.74 26.21±5.70 25.62±4.99 25.40±4.72 
  SP 24.48±2.89 23.33±3.02 23.38±3.04 23.32±4.44 
 
Mean ± SD for each experimental condition SS and SP are reported. Statistical significant 
difference is set by *P < 0.05. Oxy- (O2Hb), deoxy- (HHb), total Hb (THb) hemoglobin 
concentrations [µMol/l], (Sat) oxygen saturation in tissue [%]. 
 
Lactate Glucose and Hemoglobin Concentration 
Plasma lactate concentrations increased significantly by 10min from resting values 
of ~ 1 mmol/l (P <0.001) but stabilized thereafter and did not change significantly 
during exercise or between trials (SS, 5.01 ± 2.29 mmol/l; SP, 4.66 ± 1.85 mmol/l). 
Plasma glucose concentration decreases significantly from rest (SS, 4.69 ± 0.54 
mmol/l; SP, 4.73 ± 0.45 mmol/l) to exercise (SS, 3.97 ± 0.34 mmol/l; SP, 3.95 ± 
0.39 mmol/l), in both conditions (P <0.001). Hemoglobin concentration remains 
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stable from rest (SS, 17.34 ± 1.38 g/dl; SP, 17.13 ± 1.35 g/dl) to exercise (SS, 
17.47 ± 0.93 g/dl; SP, 17.29 ± 1.37 g/dl) condition and did not change significantly.  
 
3.4 Discussion 
This study showed that the administration of SS on healthy non-tobacco users did 
not change, compared to SP, the perception of fatigue in endurance exercise until 
exhaustion. A non-significant trend to increase in time to exhaustion (+18.6%) was 
observed after snus administration compared to placebo, similarly to a significant 
increase (+17%) described after nicotine patch administration (Mundel and Jones 
2006). Although pharmacokinetic assessment confirmed nicotine adsorption 
through snus, no effects were however observed for cardiovascular, respiratory 
and biochemical parameters compared to placebo.  
In our study, we observed a non-significant increase in time to exhaustion whereas 
Mundel and Jones found a significant effect. Interestingly, in both studies the 
magnitude in time to exhaustion increase was the same (18.6% vs. 17%). In our 
sample, three participants under snus condition showed an increase (53,7%) in 
total mean time to exhaustion. We recruited 14 participants from different sports, 
so that could be that the different training background may be a possible factor for 
inter-individual variability in time to exhaustion. If it assumed that time to 
exhaustion may be determined by the depletion of energy substrates such as 
muscle glycogen, then individual's ability to use glycogen may be a  relevant factor 
when exercise is at 70-80% of the maximum capacity aerobics (Saltin and 
Karlsson 1971). Noteworthy, we tried to control for this potential factor by asking to 
participants to maintain the same dietary conditions between the two sessions (SS 
and SP), i.e. to record their diet in the 24 h period before the EXP2, and to follow 
the same diet before each subsequent experiment.  
In literature there are only few studies that showed nicotine effect whereas for 
caffeine there are more studies suggesting an increase of time to exhaustion. 
Indeed, two recent studies (Marshall 2010; Desbrow et al., 2012) showed that 
caffeine significantly increased time to exhaustion in comparison to placebo. 
Authors concluded that, due to the side effects reported at high caffeine doses, it 
might be more beneficial for athletes to ingest low doses as the adverse effects 
may surpass the ergogenic benefits.  
We observed a non-significant effect of snus on perception of effort as similarly to 
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Mundel and Jones’s study with nicotine patch (2006). Borg’s RPE scale is an 
indicator that integrates both the perception of exertion and signals elicited from 
the peripheral working muscles and joints. Furthermore, Borg’s scale integrates 
information from the cardiovascular and respiratory functions and from the Central 
Nervous System (Borg 1982b). Borg’s RPE can be considered the more reliable 
and feasible tool for monitoring exercise intensity. Indeed, in a recent study, 
Scherr and colleagues (2013) have compared a subjective indicator of exertion 
(Borg’s RPE) to a metabolic indicator (lactate levels) and to a hearth rate (HR) of 
intensity during exercise. These authors have evaluated 2.560 Caucasian men 
and women that completed incremental exercise tests on treadmills or cycle 
ergometers. Data showed that the relationships between RPE and exercise 
intensity—assessed by blood lactate, and heart rate is strong and independent of 
age, gender, medical history, level of physical activity and exercise modality. In our 
study, five participants showed side effects whose symptoms may have masked 
changes in perception of effort during exercise.  
Our results could not be extended to regular snus users (Kobiella et al., 2011). It 
could be interesting to investigate the effects of nicotine in snus users under 
abstinence and satiety condition (for instance, similar to Escher et al., 1998, see 
below). In fact, factors such as tolerance to nicotine effects, and/or changes in 
nicotinic acethylcholine receptors availability should influence the response to 
nicotine absorbed through snus. 
Another limitation is the lack of a positive standard comparator, i.e., an 
experimental group under which perception of fatigue decrease and/or time to 
exhaustion increase. For instance, a double-blind, counterbalanced study by Killen 
and colleagues (2013) examined the effects of caffeine on session ratings of 
perceived exertion following 30 min constant-load cycling. Fifteen participants 
completed two tests following ingestion of 6 mL/kg of caffeine or placebo. Caffeine 
resulted in a significantly lower RPE for caffeine versus placebo.  
An important set of variables account to peripheral sympathetic control of 
endurance exercise. For this reason, we included in this study cardiovascular, 
respiratory, biochemical and neurophysiological assessment. No significant effects 
were seen between the two groups (SS vs. SP) for all these measurements. 
According to Van Duser and Raven’s (1992) our data also showed that anaerobic 
energy production is higher after nicotine, and that there is an early increase in 
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tachycardia response and in mean arterial pressure at relative submaximal 
workload. Nicotine is an activator of the sympathetic nervous system. These 
effects cause release of the neurotransmitter norepinephrine, skeletal muscle 
tremors, increased blood flow, elevated heart rate and blood pressure (Yoshida et 
al., 1994). Under our conditions, nicotine effect delivered by snus does not 
influence peripheral parameters probably because masked by sympathetic 
activation. The possibility to measure directly oxyhemoglobin concentration and 
deoxyhemoglobin concentration (HHb) in muscle tissue and in the frontal cortical 
areas leads us to evidence that cerebral HHb is higher in SS than in SP supporting 
the hypothesis of a major activity induced by nicotine as a central stimulator.  
Other possible CNS effects could influence performance. Escher and colleagues 
(1998) tested 20 smokeless tobacco-using athletes while both using and after 
abstaining from smokeless tobacco. The tests were reaction time, maximum 
voluntary force, and maximum rate of force generation of the knee extensors on 
dynamometer. The authors showed that smokeless tobacco use has no effect on 
reaction time but may influence maximum voluntary force and maximum rate of 
force generation. 
In conclusion, since nicotine obtained through snus under our experimental 
condition could be considered the effect of a maximal obtainable dose, we suggest 
that snus use in healthy non-smoker participants does not modify perception of 
effort and does not increase time to exhaustion on exercise endurance.  
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4. STUDY III.  
Effects of snus administration in Iowa Gambling Task in men 
 
4.1 Introduction 
Decision-making comprises a complex process of assessing and evaluating short-
term and long-term costs and benefits of competing actions. The output of the 
decision-making process is determined by an interaction between impulsive or 
emotionally based systems, responding to immediate (potential) rewards as well 
as losses or threats, and reflective or cognitive control systems controlling long-
term perspective (Bechara 2005). Research has shown that areas such as the 
ventromedial prefrontal cortex (VMPC), amygdala, insula, somatosensory cortex, 
dorsolateral prefrontal cortex and hippocampus are all involved in various aspects 
of decision-making (Bechara et al., 1999; Bechara et al., 2000; Bechara et al., 
2003; Gupta et al., 2009; Gupta el al., 2011). 
An experimental tool to study decision-making is the IGT. This test was designed 
to simulate real-life decisions in terms of uncertainty of outcomes and variable 
reward and punishment (Bechara et al., 1994). In this task, participants choose a 
card from four decks of cards. Each card indicates either gain or loss of money. 
Participants are instructed to earn as much money as possible. Two of the four 
decks are "risky", containing cards with bigger gains and losses than the other two 
decks. The sustained selection of the risky decks ends up in overall loss. 
Therefore, the choice behaviour becomes "cautious" in healthy participants during 
the task. However, patients with lesions in the prefrontal cortex and substance 
abusers persist on the risky decks. The task has been used in studies that had 
consistently demonstrate that impaired decision-making contributes to loss of 
control and substance abuse, especially when it requires appraisal of the potential 
rewards or punishments (Bechara et al., 2000). In literature some studies in 
substance abusers have assessed their performance on the IGT. Grant et al 
(2000) administered the task to poly-substance abusers versus subjects not using 
illicit drugs of abuse. Other studies have been done using IGT to test the effects of 
alcohol (Johnson et al., 2008), cocaine (Monterosso et al., 2001; Vadhan et al., 
2009), marijuana (Vadhan et al., 2007; Vaidya et al., 2012), opiate-dependent 
(Pirastu, et al., 2006) and MDMA (Quednow et al., 2006).   
Only two studies investigated the relationship between decision-making and 
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nicotine effects. Xiao and colleagues (2008) administered the IGT to 10th-grade 
Chinese adolescent smokers. Nine out of 10 of teenagers who said they had 
smoked within the previous seven days did more poorly on the IGT. Another study 
(Mitchell, 2004) demonstrated an increase in impulsive decision-making when 
smokers were deprived of nicotine but the researcher did not used the IGT. To our 
knowledge, no study has been done nicotine administered as a pure substance or 
through other nicotine-contained smokeless products by using the IGT. One of the 
popular STP consumed orally, not smoked, traditionally produced and used in 
Sweden is snus (Rutqvist et al., 2011). It is typically placed between the upper lip 
and the gum for approximately 30 min before it is discarded. Sweden is the only 
country in the EU granted special exemption to manufacture and snus sales (Anon 
1992; Ahlbom et al., 2007; Fagerström and Schildt 2003). In 2006, snus was 
introduced in USA and Alpert and colleagues (2008) reported an increasing trend 
in its use.  
Therefore, the aim of this study was to measure the effect of snus administration in 
IGT in men.  
 
4.2 Material and methods 
4.2.1 Participants 
We recruited 40 healthy men volunteers (18 – 65 years) non-smokers and non-
snus users. All participants were recruited by local advertisements in the 
metropolitan area of Verona (Italy) and in the University of Verona.  
 
4.2.2 General Design 
At EXP1 demographics of subject’s information were collected. All participants 
received the information letter to deliver to their family doctor. They were informed 
about the procedures and risks, and they signed an informed consent form before 
to start the experiment.  
The study was a double-blind crossover design study comparing the effect of 
Swedish Snus (SS) vs. Swedish Snus Placebo (SP) on IGT (Figure 11). Before 
and after IGT, subjects were administered with the Profile of Mood of State 
(POMS) questionnaire. Subjects were randomized to blindly receive SS or SP on 
EXP1 day and on EXP2 day in accordance with a random sequence generator 
schedule generated by software online (www.random.org), prior to the start of the 
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study. Session duration was approximately 75 min on EXP1 and 60 min on EXP2. 
The study was approved by the institutional ethical committees of local National 
Healthcare System Unit (ULSS20, Verona, Italy) and conformed to the 1964 
Declaration of Helsinki. 
 
 
 
Figure 11. STUDY III. Schematic representation of experimental design. Abbreviations: 
EXP1: Experiment 1; EXP2: Experiment 2; POMS: Profile of Mood State questionnaire; 
IGT: Iowa Gambling Task; SS: Swedish Snus; SP: Swedish Snus placebo. 
 
4.2.3 Protocol 
The protocol consisted of two experiments. 
EXP1. At arrival in the Neuropsychopharmacology lab in the University of Verona 
the demographics of participants were collected. The measurement of exhaled 
carbon monoxide (CO) level was performed using the EC50 Micro Smokerlyzer† 
(Bedfont Scientific Ltd.) and the average was reported in the Case Report Form 
(CRF). After CO measurement, subjects seated in front of the computer and filled 
the POMS. IGT was administering by using the same software used in Pirastu et 
al (2006). We administered SS or SP twenty-five minutes before starting IGT 
(Figure 12). During these 25 minutes subjects could read magazines, but not 
interact with technological tools such as mobile phone or computer. At the end of 
IGT, subjects spitted out the product. Immediately after, subjects were interviewed 
about adverse events (if yes, these were scored as mild, moderate or serious). At 
the end, subject filled out again the POMS questionnaire.  
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Figure 12. STUDY III. Schematic time plan design. Red bar is the estimated nicotine 
plasma concentration (the mean of Tmax is 37.1 ± 10.2 min according to Lunell and 
Curvall 2011). Abbreviations: POMS: Profile of Mood State questionnaire; IGT: Iowa 
Gambling Task; SS: Swedish Snus; SP: Swedish Snus placebo  
 
EXP2 was performed with the same procedure of EXP1 (without data collection of 
the demographic of the sample) and it took place at least 7 days later.  
 
4.2.4 Materials 
Iowa Gambling Task 
The IGT is a computerized version of the gambling task with an automated and 
computerized method for collecting data. Four decks of cards labelled A, B, C and 
D were displayed on the computer screen. The backs of the cards all look the 
same as real decks of cards. The participant started the task with a sum of make-
believe money in his or her account ($2,000), represented by a green bar that 
changes in length as the participant ‘‘wins’’ or ‘‘loses’’ money during the task. The 
subject was required to select one card at a time from one of the four decks. When 
the subject selected a card, a message was displayed on the screen indicating the 
amount of money the subject won or lost. The computer controlled the pre-
programmed schedules of gain and loss. Turning each card gave an immediate 
reward of $100 in Decks A and B and $50 in Decks C and D (Figure 12). As the 
game progressed, there were also unpredictable losses among the card selection. 
Total losses amounted to $1,250 in every 10 cards in Decks A and B compared to 
$250 in Decks C and D. Decks A and B were equivalent in terms of overall net 
loss, and Decks C and D were equivalent in terms of overall net gain over the 
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course of the trials. The difference was that in Decks A and C, the punishment was 
more frequent but of smaller magnitude, whereas in Decks B and D, the 
punishment was less frequent but of higher magnitude. Thus, Decks A and B were 
disadvantageous because they yielded high immediate gain but a greater loss in 
the long run (i.e., net loss of $250 for every 10 cards), and Decks C and D were 
advantageous in that they yielded lower immediate gain but a smaller loss in the 
long run (i.e., net gain of $250 for every 10 cards). In this study, an overall net 
score of the IGT was calculated by subtracting the total number of selections from 
disadvantageous decks (A and B) from total number selections from 
advantageous decks (C and D). We divided all 100 cards in five block cards called 
Time 1 (T1; from 1 to 21 card), Time 2 (T2; from 21 to 40 card), Time 3 (T3; from 
41 to 60 card), Time 4 (T3; from 61 to 80) and Time 5 (T5; from 81 to 100) 
respectively and we calculated the net scores values ((C + D) – (A + B)) for each 
blocks cards.  
 
 
 
Figure 12. STUDY III. Deck contingencies on the Iowa gambling task. Image taken from 
Buelow et al (2013). 
  
Snus and Placebo 
Snus (according to the GothiaTek standard) is a low-nitrosamine, moist oral 
tobacco product with water content of approximately 45%–55% and a pH of 
approximately 8.5. Lunell and Lunell (2005) describes the nicotine delivery and 
uptake from snus sachets. The mean time to maximum nicotine plasma 
concentration (Tmax) is 37.1 ± 10.2 (SD) min (range: 24–60 min) for 1 g Swedish 
portion snus (Lunell and Curvall 2011). Fagerstrom et al (2012) show a lack of 
serious AEs that require medical intervention. The placebo (SP) was almost 
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identical to the snus in physical appearance, mouth feel, pH, flavouring, and other 
sensory characteristics, but it did not contain tobacco or nicotine. The placebo is 
composed of water, oat and cocoa fibers, humectant (E422), flavor enhancer 
(sodium chloride), acidity regulator (E504, E500) and aromas. In this study we 
administrated a commercial Catch White Eucalyptus Portion Snus (Swedish 
Match) 1.0 g  - nicotine: 8 mg/portion - for SS and Onico Pepparmint  (Swedish 
Match) 1.0 g for SP respectively.  
 
POMS 
The POMS has been used extensively for the assessment of mood in the sport 
and exercise environments. This questionnaire has 58 items and the factor 
structure representing six dimensions of the mood construct: Tension, Depression, 
Anger, Vigor, Fatigue and Confusion. Items were answered on a 5-point Likert 
scale (0 = not at all, 1 = a little, 2 = moderately, 3 = quite a bit, 4 = extremely). Raw 
scores were transformed following the standard point table  (McNair et al., 1991).  
 
Smoking status 
The measurement of exhaled CO concentration, a non-invasive method of 
assessing smoking status, was measured using the EC50 Smokerlyser (Bedfont 
Instruments; Kent, UK). The Smokerlyser measures breath CO levels in parts per 
million (ppm) based on the conversion of CO to carbon dioxide (CO2) over a 
catalytically active electrode (Middleton 2000). Exhaled CO concentrations are 
reported to correlate closely with blood carboxyhaemoglobin concentration in 
smokers and in non-smokers.  
 
Data analysis 
POMS and IGT data (money win, number of choices from advantageous and 
disadvantageous decks, overall and T1, T2, T3, T4 and T5 net score) were 
analyzed using paired Student’s t-test (SS vs. SP). The normality distributions 
were tested using the Shapiro-Wilk normality test. For the data that did not have a 
normally distributions a non-parametric Wilcoxon signed-rank test was used. Then, 
to compare the condition post with the condition pre and post one sample t-test 
was used with an alternative hypothesis not equal to 100. Statistical significance 
will be accepted at P < 0.05. ANOVA. 
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4.3 Results 
Participants 
Forty non-smoker and non-snus user male subjects were recruited. Means (± SD) 
age was 23.5 ± 4.6. All subjects completed the study. The level of CO (ppm) was 
1.0 ± 0.8 before to start SS test and 1.0 ± 0.9 (means ± SD) before to start SP test. 
Values defined the subjects as non-smokers, in accordance to Deveci et al (2004).  
 
Adverse events 
Twenty-three subjects reported adverse events at the end of SS session and none 
reported effects adverse at the end of the SP session. Four subjects showed 
serious side effects as a nausea, dizziness, increase body temperature, anxiety 
and one of them reported hands tremors (Table 11). 
 
Table 11. STUDY III. Adverse effects reported by the participants at the end of the 
SS session. 
 
Subject 
Code  
Mild Moderate Serious 
RM01   Sore throat  
AF02 Confuse, Dizziness   
GM04 Dizziness   
PG06 Dizziness    
DN07   Dizziness, Sore throat  
FG08 Nausea Dizziness, Weariness  
MA09 Tachycardia    
FM13 
 
   
Stomach-ache, 
Tachycardia 
 
Nausea, Dizziness, 
Increase body 
temperature 
PG14 
 
Increase body 
temperature, Dizziness 
  
MF15 Dizziness Empty sensation  
RD17 Nausea, Dizziness   
AA19 Sleepiness Nausea, Dizziness  
AS20 Dizziness, Hands tremor    
VC22 Nausea, Hands tremor  Dizziness, Sweating  
GM26 Dizziness    
PG29   Dizziness, Tiredness Nausea 
MF30 
 
Nausea, Dizziness, 
Sweating   
 
BF33 Nausea, Confuse Dizziness, Tachycardia  
PF34   Nausea, Dizziness,  
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 Increase body 
temperature 
FF35 
 
 
 
 
 
Tachycardia 
 
 
 
Dizziness, Nausea, 
Increase body 
temperature, Hands 
Tremor 
FB36 Dizziness    
BD37 
   
Dizziness, Nausea, 
Shiver 
 
MD40 
   
Increase body 
temperature, Confuse 
Nausea, Dizziness 
 
POMS 
The POMS questionnaire was measured pre and post for all experiments. Table 
12 shows significant differences for Vigor and Confusion factors at pre vs. post 
administration for SS session; significant differences were observed for Tension, 
Depression, Anger and Confusion in pre vs. post administration for SP session in 
the six factors in a paired Student’s t-test. 
 
Table 12. STUDY III. POMS scores (mean ± SD) under SS and SP condition. 
 
Pre: pre IGT; post: post IGT. *p < 0.05, **p < 0.005, ***p < 0.0001, paired Student’s t-test 
comparison between pre exercise and post exercise in each experiment for six factors. 
 
Iowa Gambling Task 
Iowa Gambling Task data are reported in Table 13. For all participants, the 
average money won was (mean ± SEM) $ 3213 ± 140.9 during the SS session 
and $ 3140 ± 136.3 during the SP session, not significantly different (p = 0.6542; 
paired Student’s t-test). No differences were observed between number of choices 
from advantageous decks, number of choices from disadvantageous decks and 
 SS SP 
POMS factors pre  post     p value pre  post     p value 
Tension 41.7 ± 4.1 43.8 ± 9.5 0.6009 42.2 ± 4.5 41.2 ± 5.2 0.0414* 
Depression 45.5 ± 5.4 45.8 ± 8.1 0.7947 44.6 ± 5.4 43.2 ± 4.1 0.0001*** 
Anger 45.1 ± 6.5 44.1 ± 6.3 0.1769 45.3 ± 6.7 43.7 ± 4.5 0.0059** 
Vigor 56.8 ± 8.6 51.6 ± 11.7 0.0022** 55.9 ± 9.6 55.7 ± 9.6 0.8048 
Fatigue 45.4 ± 6.8 48.0 ± 10.6 0.1255 46.1 ± 9.4 44.3 ± 8.9 0.1010 
Confusion 46.6 ± 5.9 49.6 ± 7.2 0.0049** 47.2 ± 7.5 45.7 ± 7.6 0.0281* 
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overall net score (SP vs. SS) (paired Student’s t-test). Interestingly, a significant 
difference was observed for net scores in T1 between the SS and the SP condition 
(p = 0.0499). In the T2, T3, T4, and T5 net scores values in the card blocks no 
significant differences were observed (see in Figure 13). The two-way ANOVA 
(time – SS/SP) showed a non-significant interaction between time and SS/SP, F 
(4, 195) = 2.206, p = 0.0698. There was no main effect of SS/SP, F (1, 195) = 
0.3356, p = 0.5630; we did not found a significant different in time, F (4, 195) = 
1.132, p = 3427. The randomization factor (SS/SP and EXP1/EXP2), analyzed for 
a possible form of IGT’s learning between EXP1 and EXP2, did not change the 
significances. Post hoc analysis revealed the two conditions were no significantly 
different.  
 
Table 13. STUDY II. Iowa Gambling Task scores (mean ± SEM) under SS and SP 
condition. 
 
 SS SP p value 
 
Money win ($) 
 
Number of choices from advantageous decks 
Number of choices from disadvantageous decks 
Overall net score. 
 
T1 net scores 
T2 net scores 
T3 net scores 
T4 net scores 
T5 net scores 
 
 
3213 ± 140.9 
 
68.6 ± 2.5 
31.5 ± 2.5 
37.1 ± 5 
 
4.5 ± 1 
8.2 ± 1.3 
7.6 ± 1.2 
7.8 ± 1.2 
8.9 ± 1.3 
 
3140 ± 136.3 
 
69.4 ± 2.6 
30.6 ± 2.5 
38.8 ± 5.1 
 
7.0 ± 1.1 
6.6 ± 1.2 
9.1 ± 1.3 
9.0 ± 1.3 
7.0 ± 1.2 
 
0.6542 
 
0.7163 
0.7163 
0.7163 
 
0.0499* 
0.2148 
0.2645 
0.5615 
0.1554 
 
Data are expressed as means ± SEM. *p < 0.05, paired Student’s t-test comparison 
between SS and SP condition. 
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Figure 13. STUDY III. Line graph represents means net scores values (mean ± SEM) for 
each Time (T1, T2, T3, T4, T5) during SS and SP session.  
 
4.4 Discussion 
Nicotine improves cognitive functions such as learning, memory, attention, 
concentration planning and high-order executive performance (Wesnes and 
Warburton 1983; Chiamulera 2005). According to these findings Heishman and 
colleagues (2010) confirmed in their meta-analysis effects of nicotine on fine motor 
abilities, including attention and memory. Subjects were mainly nonsmokers, 
therefore avoiding confounding of nicotine withdrawal.  
This double-blind randomized study investigated the effects of SS as a source of 
nicotine on the Decision-Making (DM) process. 
IGT, an experimental tool to study DM, provides an initial random choice of decks 
where the subject is not aware of those which are advantageous and/or 
disadvantageous. Therefore, as showed in Table 12, both groups showed an initial 
net score (( C + D ) - (A + B )) lower than the final one for each block of cards. In 
the SP condition, data showed a fluctuating trend for the duration of the test, while 
in the condition SS there was a steady increase in gain (see Figure 13). According 
to Goriounova and Mansvelder (2012) the prefrontal cortex, the brain area 
responsible for executive functions and attention performance is susceptible to the 
influence of psychoactive substances such as nicotine. Observed nicotine-induced 
effects on cognitive processes in non-smokers in well-controlled studies may be 
interpreted as true effects, not confounded by the possible effects of expectancy, 
nicotine tolerance or withdrawal (Heishman et al., 1998). Furthermore, this 
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increase could be attributed to neurobiological effects of nicotine througth the 
stimulation of nicotinic receptors at the level of the pre-frontal cortex. Nicotine 
effects might have allowed the participant to identify the advantageous cards (Xiao 
et al., 2008).  
Subjects under SS condition showed an higher score, but we did not find a 
significant difference compared to the SP condition. In fact, there were no 
significant differences between SS and SP for avarage money won. Furthermore, 
no differences were observed between number of choices from advantageous 
decks, number of choices from disadvantageous decks and overall net score. 
On the other hand, Student t-test showed a significant difference (p = 0.0499) in 
the first block (T1) between the two conditions. A lower net score starting in the SS 
condition could be due to adverse effects of nicotine. In fact, the subjects under 
snus condition reported moderate dizziness, sometimes combined with nausea 
and a perceived increase in body temperature, heart rate and sweating. Dempsey 
et al (2013) observed that pharmacokinetic and genetic factors underlying 
individual differences in response to nicotine administration could influence 
sensitivity in never-smokers. 
Only two studies investigated the relationship between decision-making and 
nicotine effects. Our study was the first study that investigated snus effect in the 
human cognitive domain. Therefore, further studies are needed to demonstrate if 
snus could modify the cognitive performance. An interesting phenomenon as 
appeared in sports environment: smokeless tobacco use in sports (Marclay et al., 
2011; Zandonai et al., 2013). Considering the importance of cognition in sport, 
such an optimization of neurobiological function in our view seems to be beneficial 
for a variety of sports such as sport games or track and field (Pesta et al., 2013). It 
would be interesting to study athletes using snus under two conditions (abstinence 
and satiety) on cognitive performance tasks. Future research should be developed 
in this direction. 
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5. STUDY IV 
Acute effect of Snus on physical performance and perceived cognitive load 
on amateur footballers 
 
5.1 Introduction 
A recent review by Heishman et al (2010) points to significant effects of nicotine on 
fine motor abilities and high-order cognitive functions such as attention and 
memory. Together with changes in cognitive functioning, nicotine administration 
has been related to significant physiological effects. For instance, Turner and 
McNicol (1993) observed that nicotine administration during light physical activity 
was related to increases in heart rate and blood pressure without effects on 
pulmonary function. In this study, participants were exposed to treadmill exercise 
at an intensity corresponding to the 60% and 85% of their maximal oxygen uptake 
(VO2max) under the effects of OST. Tobacco (in comparison to a placebo condition) 
resulted in significant increases in heart rate, a decrease in stroke volume, and an 
increase in blood lactate at rest. Furthermore, due to OST-induced increase in 
plasma nicotine concentrations (boosting anaerobic energy production), a nicotine-
induced sympathetic stimulation of the heart was suggested in other research 
(Van Duser and Raven 1992). Several studies have analysed smoked tobacco 
effects on heart functions showing that nicotine was able to produce heart rate 
modulations and decreased heart rate variability (HRV) (Karakaya et al., 2007; 
Minami et al., 1999). HRV was also used to diagnose different heart diseases in 
smokers (Barutcu et al., 2005; Pope 2001), and to assess the newborn who had 
smoker mothers (Franco et al., 2000; Søvik et al., 2001). However, a study by 
Mundel and Jones (2006) has shown that nicotine (administrated by patch) 
improved exercise endurance in the absence of peripheral changes (ventilation, 
heart rate, and blood metabolites) concluding that physical enhancement was 
attained through a central nervous system mechanism.  
One easy and inexpensive way of consuming nicotine is through the use of 
smokeless tobacco products, like snus. Snus has been traditionally used in 
Sweden (Rutqvist et al., 2011), sold in small pouches. In Sweden, the increasing 
trend of snus’ use continues (Lund and Lindbak 2007) in all age groups especially 
among those that were both smokers and snus users (Norberg et al., 2011b). 
Sweden is the only nation in the European Union (EU) that granted special 
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exemption to manufacture and sell this substance (Anon 1992; Ahlbom et al., 
2007) although there is recent evidence of snus consumption in Switzerland 
(Fischer et al., 2013) and in northern Italy (Zandonai et al., 2013). Snus is of 
growing popularity in the sport environment due to absence of adverse effects on 
the respiratory system. Snus use has been associated to high intensity sports in 
which athletes report lower cigarette consumption than people not engaged in 
sport practices (Mattila et al., 2013). Some sociological studies showed that the 
use of snus was more common among team sport athletes than athletes in 
individual sports (Alaranta et al., 2006; Martinsen and Borgen 2012) and in males 
than in females (Norberg et al., 2011a; Rolandsson et al., 2014). However, there 
are no previous studies that have assessed the effects of this product in football 
players. Moreover, there are no previous studies that have investigated the effect 
of snus on physical performance, the subjective perceptions of effort, and mental 
workload in the same experiment.  
In the present study, we investigated the effect of snus acute consumption on a 
group of non-smokers non-snus users amateur football players using a test battery 
developed to assess different capacities related to physical demands in football 
(Reilly et al., 2009; Bangsbo et al., 2008). In addition, HRV was used to check the 
parasympathetic and sympathetic functioning during the experimental session. 
Crucially, perceived physical effort, subjective felt arousal, and perceived mental 
workload were also assessed. The reasons why we consider this study pertinent 
are: 1) there are no studies assessing the effects of snus on physical performance, 
perceived physical effort, and perceived mental workload in the same experiment; 
2) nicotine (the major component of snus) has been included on WADA’s 
Monitoring Program recently; 3) snus is a substance with growing popularity in 
sport; 4) No previous study has investigated the effect of snus on football players. 
Therefore, the aim of this study was to assess the effect of snus on physical 
performance, heart rate variability, and subjective arousal and mental workload in 
non-smokers non-suns users amateur football players. 
 
5.2 Materials and Methods 
5.2.1 Participants  
A total of 18 male amateur football players (age: 22.5 ± 1.5 years old; height 1.80 
± 0.056 meters; weight: 75.6 ± 7.37 kilograms; body mass index: 23.30 ± 1.44; 
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mean ± standard deviation) non-smokers and non-snus users took part in this 
study. All participants were recruited from the Faculty of Sport Sciences, University 
of Granada (Spain).  
The study was approved by the Ethics Committee of the University of Granada 
and conformed to the 1964 Declaration of Helsinki. 
 
5.2.2 General Design 
The study was a double-blind randomly assigned crossover design, comparing the 
effect of snus vs. placebo on physical performance -measured using a Fitness test 
battery-, and perceived effort -measured by the rating of perceived exertion (RPE)-
, subjective arousal, and mental workload -measured using visual analogue 
scales-. The Fitness test battery consisted of 4 tests: Handgrip Dynamometric 
Test, Counter-movement Jump, 5 x 10 meters Agility test, and Yo-yo intermittent 
recovery test.  
The protocol consisted of two sessions (EXP1 and EXP2) with 5 days of recovery 
and substance wash-out between each other. A training session was carried out a 
week before EXP1 to ensure participants’ familiarization with the tests. Half of the 
participants blindly received Swedish Snus (SS) on EXP1 day and Swedish Snus 
Placebo (SP) on EXP2 day, and the remaining half of the participants received SP 
on EXP1 day and SS on EXP2 day. Participants were randomly assigned to one of 
the two counterbalanced conditions. Each experimental session lasted for about 
90 minutes. Before and after the Fitness test battery, participant’s subjective 
arousal and mental workload was assessed (Figure 14). 
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Figure 14. STUDY IV. Protocol and experimental design. Abbreviations: EXP1: 
Experiment/assessment session 1; EXP2: Experiment/assessment session 2; VAS: visual 
analogue scale (subjective arousal and mental workload); FTB: Fitness Test Battery; SS: 
Swedish Snus; SP: Swedish Snus Placebo; n.: number of participants. 
 
5.2.3 Protocol  
Familiarization session. Participants arrived at the Faculty of Sport Sciences of the 
University of Granada, by 08.00 a.m. They were informed about the study, its 
procedure and risks, and then signed an informed consent before to start the 
experiment. Then participants performed the Fitness test battery. The 
experimenter supervised the correct performance of this test. 
EXP1. Participants arrived at 08:00 a.m. to the laboratory. Before the start of the 
experimental session, they were asked the following control questions: “How many 
hours did you sleep last night?”, and “Have you had any stimulant such as tea or 
coffee this morning before coming to the lab?”. The use of the visual analogue 
scales, the perceived readiness (PR) and perceived exertion (RPE) scales was 
subsequently explained to the participants. Then, measurement of exhaled carbon 
monoxide (CO) level was performed using the EC50 Micro Smokerlyzer† (Bedfont 
Scientific Ltd.). After this test, participants laid down for 10 minutes in a supine 
position to record their basal HRV, which was recorded during the entire session 
with a Polar RS 800 (see HRV measurement for further details). Subsequently, 
participants took the sachet of either SS or SP from the box (for further details see 
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Snus and Placebo in Materials section). They were instructed to place the SS or 
the placebo substance in the anterior part of the mouth within the upper gingiva 
(Time zero = T0) and to keep it in their mouth until performance of the Yo-Yo Test. 
After taking the SS or SP, participants were invited to remain lying on a mat during 
35 minutes in a supine position to record their HRV. Thirty-five minutes after intake 
(T0), psychological parameters (subjective arousal and mental workload) were 
recorded by means of a visual analogue scale. After 40 minutes from T0, 
participants stood up and started the Hand Dynamometric Test. Next, after a brief 
warm-up, participants performed a vertical jump test as indicator of instantaneous 
power production. The vertical jump test involved two countermovement jumps 
(Ergojump, Rome, Italy) interspersed by 1 min rest. Only the best jump from each 
subject was used in data analysis. Next, agility was assessed by means of a 10 x 
5m Agility test. After 70 minutes from T0 they spat out the corresponding 
substances (SS or SP) and started the Yo-Yo Test (Figure 15). At the end of the 
Yo-Yo Test subjective arousal and mental workload were recorded by means of 
the visual analogue scale, and immediately after participants were interviewed by 
researchers about nicotine adverse effects (if yes: mild / moderate/ serious) (Table 
13). Global RPE and readiness perception were recorded several times during the 
Fitness test battery.  
EXP2 was performed exactly following the same procedure and timetable of EXP1 
for each participant, and took place 5 days later.   
 
 
 
 
 
 
 
 
 
 
 
 
!! 61!
  
Figure 15. STUDY IV. Schematic time plan design. Red bar is the estimated nicotine 
plasma concentration (the mean of Tmax is 37.1 ± 10.2 min according to Lunell and 
Curvall, 2011). Abbreviations: SS: Swedish Snus; SP: Swedish Snus Placebo; RPE: 
rating perceived exertion (Borg’s scales); CQ: control questions; VAS: visual analogic 
scale (subjective arousal and mental workload); PR: perceived readiness; HDT: hand 
dynamometric test; CMJ: countermovement jump; AT: agility test; SO: substance (Snus / 
Placebo) out; YYT: Yo-yo intermittent test; SEI: side effects interview; HRV: heart rate 
variability. 
 
5.2.4 Materials 
Snus and Placebo 
Snus is a low-nitrosamine, moist oral tobacco product with water content of 
approximately 45%–55% and a pH of approximately 8.5. For Snus and Placebo 
delivery and uptake we followed Lunell and Lunell (2005) methodology. The mean 
time to maximum nicotine plasma concentration (Tmax) is 37.1±10.2 (SD) min 
(range: 24–60 min) for 1 g Swedish portion snus (Lunell and Curvall 2011). 
Fagerstrom et al., (2012) show a lack of serious AEs that require medical 
intervention. The placebo (SP) was almost identical to the snus in physical 
appearance, mouth feel, pH, flavouring, and other sensory characteristics, but it 
did not contain tobacco or nicotine. The placebo is composed of water, oat and 
cocoa fibers, humectant (E422), flavor enhancer (sodium chloride), acidity 
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regulator (E504, E500) and aromas. In this study, we administrated a commercial 
Catch White Eucalyptus Portion Snus (Swedish Match) 1.0 g - nicotine: 8 
mg/portion - for Snus and Onico Pepparmint  (Swedish Match) 1.0 g for Placebo 
respectively.  
 
Smoking status 
The measurement of exhaled CO concentration, a non-invasive method of 
assessing smoking status, was measured using the EC50 Smokerlyser (Bedfont 
Instruments; Kent, UK). The Smokerlyser measures breath CO levels in parts per 
million (ppm) based on the conversion of CO to carbon dioxide (CO2) over a 
catalytically active electrode (Middleton and Morice 2000). Exhaled CO 
concentrations are reported to closely correlate with blood carboxyhaemoglobin 
concentration in smokers and in non-smokers.  
 
Arousal and mental workload 
Before Snus or Placebo ingestion and immediately after finishing the Fitness test 
battery participants were asked to rate their perceived arousal and perceived 
mental and physical fatigue using a visual analogue scale from 0 (nothing) to 10 
(top) in response to the following questions: 
1) “What is your activation level now?” 
2) “What is your physical fatigue level now?”  
3) “What is your mental fatigue level now?” 
At the end of the session, participants were asked to use the visual analogue scale 
again according to the following questions:  
1) “Finally, how would you rate the overall mental load for this experimental 
session?” 
2) “How do you feel now, once the session has finished?”  
 
Rating of Perceived Exertion  
Rating of perceived exertion was measured with the Borg 15 point scale (RPE 6-
20) (Borg et al., 1985) and with a 10-point category-ratio (RPE CR10) (Noble et 
al., 1983). Participants were given verbal encouragement during the fitness tests. 
Immediately after the handgrip test, Counter-movement Jump, and Yo-Yo Test 
RPE were asked.  
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Perceived readiness 
The value for perceived readiness (1-5 scale) (Nurmekiv et al., 2001) was also 
taken prior to the handgrip and Yo-Yo tests. This scale determines the grade of 
recovery that subjects perceived from 1-point (“not recovered at all”) to 5-points 
(“completely recovered”). Before beginning the handgrip and Yo-Yo Test ratings of 
perceived readiness were asked. 
 
HRV measurement 
Recordings were performed using a Polar RS800 HR monitor set to RR interval 
mode (Polar Electro, Kempele, Finland) together with an electrode transmitter belt 
(Polar Wearlink Wind, Polar Electro, Kempele, Finland), after application of 
conductive gel as recommended by the manufacturer. Data were transferred to 
Polar Pro Trainer 5 software (Polar Electro, Kempele, Finland) and afterwards 
analysed by means of Kubios HRV Analysis Software 2.1 (The Biomedical Signal 
and Medical Imaging Analysis Group, Department of Applied Physics, University of 
Kuopio, Finland). 
 
Handgrip dynamometry 
An electronic dynamometer (Takei TKK-5401, Tokio, Japan) was used to 
determine handgrip strength in both right and left hands. The dynamometer was 
adjusted for each subject's hand size and the participants were kept in stand 
position with the arms parallel to the ground and with the elbow joint maintained at 
90 degrees of flexion. The participants were instructed to perform a maximal 
isometric contraction. Each subject was allowed 2 trials non-consecutive per arm, 
and the highest value was recorded. 
 
Countermovement jump 
Muscle power was evaluated using a wireless inertial measurement unit 
(FreePower®, Sensorize, Rome, Italy), which was validated by Squadrone et al 
(2012). Two standardized counter-movement jumps separated by 2-min rest 
interval were performed. The wireless inertial measurement unit of FreePower® 
was positioned approximately at the centre of body mass, placing the belt around 
the waist. Participants started from a standing position with hands on their hips 
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and were instructed to perform a fast downward movement up to 90° of knee 
flexion followed by an upward movement trying to jump as high as possible. 
Maximum jump height was registered for further analysis.  
 
Agility test (5x10) 
Agility was evaluated using a 10 x 5 meters maximal shuttle run on an indoor 
running track following the protocol of Eurofit (1998). After 1 practice trial a 
maximum test was performed. Performance time was recorded with an accuracy 
of 0.01 seconds using Chronometer application for Iphone 4. 
 
Yo-Yo recovery intermittent test 
The Yo-Yo test was performed using the level-1 version of the test, following the 
guidance defined by the test’s creator (Bangsbo 1996). The level-1 Yo-Yo test is a 
progressive shuttle running test that allows 10 seconds of active recovery after 
every second 20 meters shuttle. Running speeds are dictated by an audible cue 
played from a CD. Participants must be at one end of a 20 meters base every time 
a signal is played. Yo-Yo test performance is considered as the total distance 
covered by the subject when they drop out. 
 
Data analysis 
Data are presented as mean values ± SD and were analysed with IBM SPSS 20.0 
using paired-sample t-tests to compare differences between the SS and SP 
ingestions conditions. In order to address any learning/familiarization effect, data 
from EXP1 and EXP2 were compared using paired-sample t-tests. Bonferroni 
post-hoc correction for multiple comparisons was applied obtaining a level of 
significance of p=0.003. 
For HRV data, the recordings were preprocessed to exclude artifacts by 
eliminating RR intervals, which differed more than 25% from the previous, and the 
subsequent RR intervals (Malik et al., 1989). Removed RR intervals were replaced 
by conventional spline interpolation so that the length of the data did not change 
(i.e., resulting in the same number of beats). We used the smoothness prior 
method with a Lambda value of 500 to remove disturbing low frequency baseline 
trend components (Tarvainen et al., 2002). Regarding linear analysis during the 
experimental conditions, the mean R-R interval (RRi), root-mean-square difference 
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of successive normal R-R intervals (rMSSD) were calculated for the time domain. 
Geometric Poincaré Plot index (SD1) was also calculated.  
 
5.3 Results 
No significant differences were found between data from EXP1 and EXP2 (all 
ps>0.003), showing that there were no learning or fatigue carry-over effects across 
experimental sessions. 
 
Control variables 
No significant differences were observed in relation to sleeping hours between 
Snus (6.94±1.11) and placebo (6.67±1.09) sessions. Regarding Smoking status 
assessment, the level of CO (ppm) before completion of the fitness battery test 
was 2.97±1.45 for the snus condition and 3.54±3.83 for the placebo condition 
respectively. Values defined the participants as non-smokers, in accordance to 
Deveci et al (2004).  
Results for all dependent variables (Subjective arousal, perceived mental 
workload, Rate Perceived Exertion, Perceived readiness, HRV measurement, 
Handgrip dynamometry, Countermovement jump, Agility test, Yo-Yo test) for snus 
and placebo conditions are shown in Table 14.  
Regarding HRV measurements, our data showed a significant effect in the snus 
condition (basal measure before intake vs. after intake) in the RRi, rMSSD and 
SD1 variables. No significant differences were observed in the placebo condition. 
No significant differences before substance intake were observed between the SS 
and SP conditions. Interestingly, there were significant differences for all HRV 
variables when comparing the snus and placebo conditions after substance intake  
(Table 15).   
 
Side effects 
Twelve participants reported adverse symptoms at the end of the snus condition 
session and only one reported adverse effects at the end of the placebo condition 
session (Table 16). Due to these adverse effects some participants could not 
complete all assessments during the experimental session. This is the reason of 
the reduced N in some of the statistical comparisons (see Table 15). 
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Table 14. STUDY IV. Comparison (Bonferroni corrected α=.003) between the SS and SP conditions for all dependent variables 
included in this study. (Perceived mental workload, Subjective arousal, Rate Perceived Exertion, Perceived readiness, HRV 
measurement, Handgrip dynamometry, Countermovement jump, Agility test, Yoyo recovery intermittent test).  
 
 
SS SP p 
 mean  SD SE mean  SD SE   
CQ1 Sleeping hours 6.94 1.11 0.26 6.68 1.08 0.26 0.097 
Smokerlyzer (ppm) 2.97 1.45 0.34 3.53 3.82 0.90 0.563 
VAS1 after intake, before FTB (0-10) 4.83 1.85 0.44 5.11 1.74 0.41 0.523 
VAS2 after intake, before FTB (0-10) 4.00 2.22 0.52 3.89 2.03 0.48 0.734 
VAS3 after intake, before FTB (0-10) 4.17 2.38 0.56 2.94 1.89 0.45 0.005 
Perceived readiness before Handgrip test (1-5) 3.71 0.82 0.22 4.43 0.51 0.14 0.001 
Handgrip right (Kg) 42.22 5.63 1.33 42.06 4.46 1.05 0.834 
Handgrip left (Kg) 37.22 6.28 1.48 38.33 4.73 1.11 0.068 
RPE CR10 after Handgrip test 5.72 2.24 0.53 5.67 2.14 0.51 0.842 
RPE 6-20 after Handgrip test 14.89 2.85 0.67 14.44 2.62 0.62 0.177 
Maximum Jump height (m) 0.43 0.05 0.01 0.44 0.05 0.01 0.634 
RPE CR10 after CMJ 6.06 1.87 0.46 5.94 2.11 0.51 0.707 
RPE 6-20 after CMJ 14.59 2.55 0.62 14.71 2.14 0.52 0.743 
Agility Test (seconds) 18.82 0.81 0.20 18.47 0.62 0.15 0.009 
Perceived readiness before YYT (1-5)* 3.60 0.84 0.27 4.00 0.67 0.21 0.037 
Distance YYT (m)* 1397.14 447.14 119.50 1.407.86 481.92 128.79 0.926 
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VO2max YYT (ml*kg*min) * 48.28 3.75 10.03 48.23 4.05 10.81 0.952 
RPE CR10 after YYT* 9.41 1.12 0.29 9.20 1.61 0.42 0.556 
RPE 6-20 after YYT * 18.67 0.98 0.25 18.53 1.51 0.39 0.685 
Mental load after session  (0-10) 6.37 2.16 0.54 5.44 1.82 0.46 0.001 
VAS1 after session (0-10) 7.19 1.97 0.50 7.37 1.31 0.33 0.628 
VAS2 level after session (0-10) 7.87 1.71 0.43 8.00 1.46 0.36 0.783 
VAS3 level after  session (0-10) 7.12 1.71 0.43 6.44 1.37 0.34 0.102 
RPE CR10 after session 7.87 1.85 0.48 7.60 0.99 0.25 0.556 
RPE 6-20 after session 16.67 2.38 0.61 16.60 0.91 0.23 0.927 
 
Abbreviations: SD: Standard deviation; SE: Standard error; VAS: Visual Analogue Scale -subjective arousal and mental workload-; VAS1: 
Activation level; VAS2: Physical fatigue level; VAS3: Mental fatigue level; FTB: Fitness Tests Battery CMJ: Countermovement jump; YYT: 
Yoyo recovery intermittent test; VO2max: maximal oxygen uptake; n = 18; * n=14. 
 
Table 15. STUDY IV. HRV measurements. 
 
  SS SP 
  RRi rMSSD SD1 RRi rMSSD SD1 
Basal 948.85 ± 119.72* 62.09 ± 28.30* 43.99 ± 20.06* 895.41 ± 131.74 62.76 ± 23.36 44.33 ± 16.59 
Activity 665.19 ± 98.21‡ 50.11 ± 28.29‡ 35.22 ± 19.45‡ 887.28 ± 137.54 72.32 ± 30.56 51.23 ± 21.66 
 
* p<0.05 Basal vs. Activity condition; ‡ p<0.05 Snus (SS) vs. Placebo (SP) condition. 
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Table 16. STUDY IV. Side effects described by the participants that reported them 
at the end of the their SS session. 
 
Subject Code Mild Moderate Serious 
01AAJ  Tachycardia  
02CCJ   Confuse, Dizziness 
03CGJ   Nausea, Dizziness 
04CBI Dizziness Stomach-ache 
Empty sensation, 
Tiredness, Confuse 
05EGA Tiredness   
07LMJ Dizziness   
09RLF Sore throat   
11SSS  Nausea, Dizziness  
12BNV Tiredness Dizziness  
13HJE Dizziness  Nausea 
16PGM 
 
Dizziness 
 
Sweating,  
Increase body 
temperature 
Tremor 
17MA  Dizziness, Sweating 
Empty sensation, 
Nausea 
 
5.4 Discussion   
Nicotine is the main psychoactive substance present in tobacco, targeting 
neuronal nicotinic acetylcholine receptors (Ortells and Arias 2010). This 
psychoactive substance has been shown to increase muscle blood flow (Weber et 
al., 1989), heart rate, blood pressure, level of circulating catecholamine, and 
vasoconstriction during light exercise (Walker et al., 1999; Cryer et al., 1976). In 
the present study we investigated the effect of snus (a current common form of 
tobacco consumption) on physical and mental workload on a sample of amateur 
sportsmen (football players). 
Results from the present study showed that amateur footballers heart rate 
variability, subjective arousal and mental workload perceptions, and fitness 
performance were impaired by acute snus intake. Crucially, participants’ perceived 
readiness before some fitness tests, and total mental load after the experimental 
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session, were also boosted as a consequence of snus administration. In addition, 
4 of 18 participants (22%) could not complete the fitness test battery due to 
dizziness, tachycardia, cold sweats and other SS side effects. Regarding 
participants’ HRV, the results showed a decrease after SS administration even 
before the beginning of the fitness test battery. The results appear to confirm that 
nicotine leads to reduce vagal tone (Karakaya et al., 2007) as indexed by the 
rMSSD parameter. The effect of SS was also observed on all the HRV variables 
analysed compared to the placebo condition.  
Our study goes beyond previous research that has investigated the effect of 
nicotine on HRV (Barutcu et al., 2005; Franco et al., 2000; Karakaya et al., 2007; 
Minami et al., 1999; Pope 2001). Indeed, these studies used smoked tobacco, 
and, consequently, they did not control for possible respiratory disorders 
(Kharitonov et al., 1995), which could have influenced the observed HRV patterns 
(Hayano et al., 1994). On the contrary, in our study, we were able to avoid 
possible respiratory disruption focusing on vagal alteration produced by nicotine by 
administering the product orally. 
As already noted, significant beneficial effects of nicotine have been observed on 
motor abilities and other high-order cognitive functions (see Heishman et al., 2010, 
for a review) suggesting relevant performance enhancement (Pesta et al., 2013). 
In particular, significant positive effects of nicotine have been shown on at least six 
cognitive domains: fine motor coordination, alerting and spatial attention, short-
term episodic memory, and working memory (Heishman el al., 2010). Most 
published studies support that nicotine causes cognitive enhancement in smokers 
but the influence of nicotine on human performance in non-smokers is less clear. 
While some studies have failed to detect nicotine-induced cognitive enhancement 
(Foulds et al., 1996; McClernon et al., 2003) others have even found impairment 
effects (Heishman et al., 1993).  
In our study, participants showed reduced perceived readiness before the 
Handgrip dynamometry test in the SS condition compared to the SP condition. In 
the same way, 35 minutes after SS intake, larger mental fatigue values were 
reported than in after SP intake. Furthermore, once the Yo-Yo Test finished (at the 
end of the experimental session) participants reported higher mental workload in 
the SS condition than in the SP condition. Therefore, snus had a negative effect 
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on perceived mental workload, even before starting the physical tests. Perceived 
arousal was also greater in the SS condition than in the SP condition. Regarding 
this latter result, research suggests that the effects of nicotine on subjective 
arousal are dose dependent (Perkins and Stitzer 1998) with mild positive effects at 
low doses, moderate positive effects at intermediate doses, and negative effects at 
high doses (Kalman and Smith 2005). Therefore, it is possible that the nicotine 
intake level achieved in our study was pharmacologically equivalent to a high 
dose, considering the lack of tolerance in our nicotine-naïve participants. This 
explanation could be extended to the perceived readiness and perceived mental 
workload results, explaining the apparent inconsistent results from studies with 
non-smokers mentioned above. In contrast to the subjective ratings of mental 
workload and arousal, ratings of Perceived Exertion (RPE) did not differ between 
the SS and SP conditions. This is consistent with previous studies (Mundel and 
Jones 2006) that analyzed the effects of nicotine patch on healthy non-smokers 
and did not observed significant modifications in RPE compared to placebo. Taken 
together, our results point to a negative effect of snus on subjective evaluation of 
cognitive load and arousal.  
The difference in performance in the Agility test between the two experimental 
conditions (SS vs. SP) is an interesting result. We suggest that participants 
performed better under the effects of placebo due to the absence of nicotine side 
effects on the vestibular system. In fact, Zingler et al (2007) observed that nicotine 
in non-smokers causes dose-dependent adverse perceptual, ocular motor, 
vegetative, and postural imbalance effects. These effects can be related to a 
pharmacological stimulation of the vestibular circuitry. Moreover, given the 
negative effect of SS on subjectively perceived mental load and arousal, and the 
high demands of fast responding of the Agility test, one might wonder whether SS 
intake resulted in lower reaction times to the start of the test. Note that this is 
highly speculative since we did not collect participants’ reaction times, and further 
research is needed to address this issue.    
In contrast to the abovementioned results, no differences between the SS and SP 
conditions were found for Handgrip dynamometry test, Counter-movement jump, 
and Yo-Yo test. Furthermore, we found no significant variations under the two 
experimental conditions (SS vs. SP) for most of the tests in the Fitness test battery 
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which contrast with previous literature that have observed the effect of other 
psychoactive substance (such as caffeine) when using the same tests (Gant et al., 
2010; Mohr et al., 2011). For instance, Gant et al (2010) showed that caffeine 
administration improved counter-movement jump performance. Moreover, Mohr 
and colleagues (2011) reported that high-intensity intermittent exercise 
performance Yo-Yo test was significantly improved by oral caffeine administration 
in comparison with placebo.  
Nicotine absorption varies greatly among individuals. However, according to Lunell 
and Lunell (2005) the variation in nicotine extraction rates among different snus 
users could range from 50 to 300 percent in a same snus user since the amount of 
extracted nicotine could be partially an effect of the intensity with which that 
portion is manipulated in the mouth. In addition, nicotine side effects may differ 
between non-smokers and smokers due to tolerance and neuroadaptive 
processes during prolonged nicotine use (Kobiella et al., 2010). Our study with 
non-smokers and non-snus users, showed that twelve participants reported after 
SS administration adverse events such as increased heart rate, dizziness, and 
nausea (Table 16). Possible explanations could be found in the amount of nicotine 
absorbed and excessive sensibility to nicotine. It is likely that, as non-smokers, 
participants were not tolerant to nicotine unpleasant effects. In fact, four 
participants had to suspend their participation in the fitness test battery before 
starting the Yo-Yo Test due to serious sides effects (see Table 16, participants 2, 
3, 4, and, 13).  It is important to note that, compared to rest, exercise can lead to 
increase in plasma nicotine levels and toxicity due to increased drug absorption 
during physical exercise (Lenz et al., 1999). 
Apart from the side effects reported above, the effect of nicotine varies as a 
function of nicotine habituation. It would be therefore interesting for future research 
to investigate the effects of nicotine on smokers athletes and/or snus users, 
comparing objective and subjective physical and mental performance under 
conditions of satiety and abstinence. Indeed, SS effects could have been different 
on non-smokers participants after a familiarization process with this substance 
although an unethical risk of addiction could appear, which is not in line with the 
“fair play” and the education of the ideal “athlete 2.0” that rejects the improvement 
of performance despite the possible health damage (Zabala and Atkinson 2012). 
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In snus there are presents in addition to tobacco and water, various other 
ingredients as sodium chloride, sodium carbonate, humectants, and flavoring 
agents (Rutqvist et al., 2011). One of the limits of this study it is that we did not 
analyzed nicotine plasma levels concentration to exclude the effect of other 
substances. 
In sum, the results of the present study revealed that amateur footballers’ heart 
rate variability, felt arousal, and mental workload perceptions, and performance in 
an agility physical test were impaired by acute SS intake. Therefore, taken 
together, these data argue against snus as an efficient ergogenic aid. 
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6. CONCLUSIONS 
In this research project there were some limitations.  
In STUDY I the sample size recruited to compare the relationships between snus 
and smoking was limited. Studies would be performed based on much larger 
population.  
In the experimental studies (STUDY II, III and IV) the aim was to investigate 
whether snus improves performance in subjects with no prior experience of snus. 
We gave them no opportunity to trial the snus and become familiar with it.  
Therefore when they were given snus in these studies they would have suffered 
the aversive effects, which could have limited their tolerance. They would practice 
exercising with snus on many occasions and would develop tolerance to its 
aversive effects. 
Under our experimental conditions in non-smokers non-snus users healthy male 
subjects did not improve psycho-physiological and cognitive performance. A 
multidisciplinary experimental approach to investigate the effects of nicotine by 
snus on smoker athletes and/or snus users, during exercise and cognitive 
performance under satiety and abstinence conditions is needed. Further 
researches should be designed on new models mimicking field conditions to 
producing evidence-based data.  
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